US20210138015A1 - Olive derived cell culture and methods for preparing and using the same - Google Patents
Olive derived cell culture and methods for preparing and using the same Download PDFInfo
- Publication number
- US20210138015A1 US20210138015A1 US17/155,059 US202117155059A US2021138015A1 US 20210138015 A1 US20210138015 A1 US 20210138015A1 US 202117155059 A US202117155059 A US 202117155059A US 2021138015 A1 US2021138015 A1 US 2021138015A1
- Authority
- US
- United States
- Prior art keywords
- olive
- bioreactor
- medium
- cells
- large scale
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000007817 Olea europaea Species 0.000 title claims abstract description 336
- 238000000034 method Methods 0.000 title claims abstract description 97
- 238000004113 cell culture Methods 0.000 title claims description 112
- 230000008569 process Effects 0.000 claims abstract description 78
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 45
- KDSWDGKIENPKLB-QJDQKFITSA-N verbascoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)CCC=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O KDSWDGKIENPKLB-QJDQKFITSA-N 0.000 claims abstract description 45
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 42
- 238000000338 in vitro Methods 0.000 claims abstract description 27
- 229930006000 Sucrose Natural products 0.000 claims description 57
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 57
- 239000005720 sucrose Substances 0.000 claims description 57
- 239000006870 ms-medium Substances 0.000 claims description 54
- 239000001963 growth medium Substances 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 229920001817 Agar Polymers 0.000 claims description 24
- 239000008272 agar Substances 0.000 claims description 24
- 239000005971 1-naphthylacetic acid Substances 0.000 claims description 23
- IIDAJRNSZSFFCB-UHFFFAOYSA-N 4-amino-5-methoxy-2-methylbenzenesulfonamide Chemical compound COC1=CC(S(N)(=O)=O)=C(C)C=C1N IIDAJRNSZSFFCB-UHFFFAOYSA-N 0.000 claims description 23
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 claims description 17
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 claims description 17
- 229960001669 kinetin Drugs 0.000 claims description 17
- -1 polyethylene Polymers 0.000 claims description 14
- 235000002725 Olea europaea Nutrition 0.000 claims description 8
- 108010079058 casein hydrolysate Proteins 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 7
- 238000003306 harvesting Methods 0.000 claims description 7
- 229920000573 polyethylene Polymers 0.000 claims description 7
- 239000003610 charcoal Substances 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000003375 plant hormone Substances 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 239000000843 powder Substances 0.000 abstract description 83
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 abstract description 73
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 abstract description 36
- 235000004330 tyrosol Nutrition 0.000 abstract description 36
- 239000000203 mixture Substances 0.000 abstract description 29
- 206010020649 Hyperkeratosis Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 229930000044 secondary metabolite Natural products 0.000 description 77
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 67
- 239000002609 medium Substances 0.000 description 62
- 150000008442 polyphenolic compounds Chemical class 0.000 description 56
- 235000013824 polyphenols Nutrition 0.000 description 55
- 239000000463 material Substances 0.000 description 35
- 235000003248 hydroxytyrosol Nutrition 0.000 description 33
- 229940095066 hydroxytyrosol Drugs 0.000 description 33
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 32
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 31
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 31
- 235000011576 oleuropein Nutrition 0.000 description 31
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 31
- 239000007789 gas Substances 0.000 description 27
- 241000196324 Embryophyta Species 0.000 description 20
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 19
- 230000012010 growth Effects 0.000 description 19
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 13
- 239000000725 suspension Substances 0.000 description 11
- 230000010261 cell growth Effects 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000004114 suspension culture Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000013028 medium composition Substances 0.000 description 9
- 239000002028 Biomass Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 241000826760 Barnea Species 0.000 description 7
- 241000699729 Muridae Species 0.000 description 7
- 241000207836 Olea <angiosperm> Species 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000002417 nutraceutical Substances 0.000 description 7
- 235000021436 nutraceutical agent Nutrition 0.000 description 7
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 7
- 235000007221 pinoresinol Nutrition 0.000 description 7
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 235000009692 Crataegus pubescens Nutrition 0.000 description 5
- 244000217406 Crataegus pubescens Species 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 4
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 4
- 235000012734 epicatechin Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 3
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- HXKWSTRRCHTUEC-UHFFFAOYSA-N 2,4-Dichlorophenoxyaceticacid Chemical compound OC(=O)C(Cl)OC1=CC=C(Cl)C=C1 HXKWSTRRCHTUEC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001483078 Phyto Species 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940068517 fruit extracts Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 229930010796 primary metabolite Natural products 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GMQXOLRKJQWPNB-UHFFFAOYSA-N (8E)-ligstroside Natural products CC=C1C(CC(=O)OCCC=2C=CC(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O GMQXOLRKJQWPNB-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014486 Elevated triglycerides Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 235000021506 Ipomoea Nutrition 0.000 description 1
- 241000207783 Ipomoea Species 0.000 description 1
- 235000013757 Juglans Nutrition 0.000 description 1
- 241000758789 Juglans Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- GMQXOLRKJQWPNB-JSTGBQKGSA-N Ligstroside Natural products COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)C(=CC)[C@@H]1CC(=O)OCCc3ccc(O)cc3 GMQXOLRKJQWPNB-JSTGBQKGSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003525 auxine Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- QWEKFUBDXQTUTJ-LRPGRGPISA-N demethyloleuropein Chemical compound O([C@H]1C([C@@H](C(=CO1)C(O)=O)CC(=O)OC=CC=1C=C(O)C(O)=CC=1)=CC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWEKFUBDXQTUTJ-LRPGRGPISA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- GMQXOLRKJQWPNB-MVVLSVRYSA-N ligstroside Chemical compound O([C@@H]\1OC=C([C@H](C/1=C\C)CC(=O)OCCC=1C=CC(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMQXOLRKJQWPNB-MVVLSVRYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011684 sodium molybdate Substances 0.000 description 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000011686 zinc sulphate Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/08—Fruits
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H4/00—Plant reproduction by tissue culture techniques ; Tissue culture techniques therefor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
- A01H5/00—Angiosperms, i.e. flowering plants, characterised by their plant parts; Angiosperms characterised otherwise than by their botanic taxonomy
- A01H5/10—Seeds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0025—Culture media for plant cell or plant tissue culture
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D88/00—Large containers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/14—Bags
Definitions
- the invention is directed to olive derived cell cultures, a process for the large scale production of such cell cultures, as well as methods of using the same.
- Nutraceuticals are sometimes prepared using synthetic processes that provide the desired active ingredients, e.g., polyphenols, which are naturally found in fruit cells. However, the use of synthetic processes does not provide the natural ingredients along with the active ingredients, which sometimes contribute to the efficiency of the formulation.
- nutraceuticals are prepared from the natural plants; however, all known large scale processes for preparing nutraceuticals from plants include the extraction of the prepared plant cells in order to obtain the desired active ingredient. However, when plants containing polyphenols, for example, are extracted, the final product may be bitter. Also, only certain parts of the plant may be successfully extracted since only they contain the desired amounts of the active ingredients.
- Nutraceuticals derived from polyphenol-containing fruit extracts are known for their beneficial effects. However, it has been shown that the therapeutic effect of fruit extracts is dependent on species, location, year (annual climate), processing etc. and therefore reliance on natural fruits as a source of these regulatory compounds does not lead to a homogeneous or consistent supply of material. Furthermore, fruits are often contaminated by residual fungicides, pathogens, pesticides and pollutants.
- Polyphenols content of olive fruits contain primarily phenolics, terpenes and sterols, all of which are present in various plant parts, such as, bark, leaf and fruit.
- the major phenolic compounds are oleuropein, demethyloleuropein, 3-4 DHPEA-EDA, ligstroside, tyrosol, hydroxytyrosol, verbascoside and lignans (Alagna et al. BMC Plant Biology 2012, 12:162).
- Tyrosol, hydroxytyrosol, oleuropein and verbascoside are all known for their potent antioxidant capacity. These compounds are the major polyphenols in olive, and are responsible for the high antioxidant activity of olives and olive oil.
- compositions that may be prepared in a large scale process in which the amount of the active ingredient/s is similar or higher than in olive plants, including the leaves. Further, compositions prepared in a large scale process would prove to be and be consistent and recurrent (e.g., clonal preparations) and therefore, would be advantageous over olive secondary metabolites obtained by other methods.
- Embodiments of the invention are directed to a large scale process for the in vitro production of an olive cell culture of olive cells grown comprising: growing olive cells in a flask;
- the second bioreactor is a last bioreactor or an intermediate bioreactor and wherein the olive cells harvested from the last bioreactor are dried.
- the size of each bioreactor used in the process is larger than the one in which the olive cells were previously grown.
- the second bioreactor is an intermediate bioreactor
- an additional step of inoculating the olive cells to another intermediate bioreactor or to the last bioreactor is performed.
- the large scale process of the invention further includes additional steps of inoculating the olive cells from the second bioreactor into any number of sequential intermediate bioreactors.
- any one of the bioreactors is a 4-10 liter bioreactor. According to some embodiments, any one of the bioreactors is a 10-50 liter bioreactor. According to some embodiments, any one of the bioreactors is a 50-200 liter bioreactor. According to some embodiments, any one of the bioreactors is a 200-500 liter bioreactor. According to some embodiments, any one of the bioreactors is a 200-1000 liter bioreactor.
- the olive cells are grown in bioreactors comprising a growth MS medium as defined in Table 1B supplemented with different hormones and various sucrose concentrations e.g.
- the olive cells are grown in bioreactors comprising a growth MS medium comprising one or more of kinetin, sucrose, 2,4,D, NAA, 2iP, BA or any combination thereof.
- the olive cells are grown in bioreactors comprising a growth MS medium comprising agar and one or more of kinetin, sucrose, 2,4,D, NAA, 2iP, BA or any combination thereof.
- composition of each or those media which in essence is a modification of the MS medium, is as detailed in the table below:
- composition of the MS medium is as follows:
- the olive calli cells are grown in modified MS medium.
- the modified MS medium comprises:
- the olive cells growing in vitro suspension are grown in modified MS medium.
- the modified MS medium that can be used for the suspension are same as those described for the growth of the olive calli but do not comprise agar:
- the olive calli cells are grown in modified MS medium.
- the modified MS medium comprises:
- the olive cells growing in suspension are grown in modified MS medium.
- the modified MS medium comprises:
- the growth medium is enriched with sucrose, casein hydrolysate, myo inositol, 1-naphthaleneacetic acid (NAA), kinetin, 2,4,D (2,4-Dichlorophenoxyacetic acid), BA (benzyladenine), 2iP (6-dimethylamino purine), or any combination thereof.
- the growth medium does not include plant hormones.
- the growth medium includes plant hormones.
- the growth medium is enriched with 1-6% sucrose.
- the disposable bioreactor is made from one or more layers of polyethylene.
- the disposable bioreactor includes an inner and an outer layer prepared from polyethylene and a middle layer prepared from nylon.
- compositions in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of section: olive pulp, olive seed, olive petiole or olive leaf.
- the olive fruit cells include polyphenols, such as, hydroxytyrosol, tyrosol, oleuropein, verbascoside and pinoresinol, but not limited only to these types.
- the olive fruit cells prepared include polyphenols selected from hydroxytyrosol, tyrosol, oleuropein, verbascoside and pinoresinol.
- the olive cells grown in vitro in a large scale process are prepared according to the large scale process of the invention, as detailed herein.
- Additional embodiments of the invention are directed to olive calli culture comprising verbasco side in the amount of at least 8.2 ⁇ g/mg dry weight.
- the second bioreactor is a last bioreactor or an intermediate bioreactor and wherein at least one of the first and the second bioreactor is disposable and wherein the olive cells harvested from the last bioreactor are dried.
- the invention provides a composition in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of section: olive pulp, olive seed, olive petiole or olive leaf.
- the invention provides a method of prevention and/or treatment of risk factors for cardiovascular disease, development of atherosclerotic plaque, protection of LDL particles from oxidative damage, maintenance of normal blood HDL-cholesterol concentrations, decrease of high blood pressure and to maintain normal haemostatic function.
- Olive polyphenols were shown to have beneficial effects on learning and memory deficits found in ageing and diseases, such as those related to the overproduction of amyloid-beta peptide.
- olive polyphenols were shown to influence gut microbial balance by promoting growth of bacteria influencing lipid metabolism and inhibition of pathogenic bacteria.
- the method comprising administering an effective amount of a composition comprising composition in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of cross section, olive pulp, olive seed, olive petiole or olive leaf.
- the olive cells culture is grown in vitro under dark conditions.
- the olive cells culture is grown in vitro under fully dark conditions (24 hours a day).
- FIG. 1 presents an HPLC chromatogram at 280 nm of olive polyphenols derived from olive cells grown in O4 medium (modified MS medium);
- FIG. 2 presents olive cell growth in large bioreactors in O4 medium (modified MS medium).
- Embodiments of the invention are directed to a composition in a form of a powder comprising a cell culture of olive cell culture (OC) grown in vitro in, whereby the cell culture of OC is derived from one or more of olive sections: olive pulp, olive seed, olive petiole or olive leaf.
- the cell culture of OC includes tyrosol, hydroxytyrosol, oleuropein and verbascoside in an amount of at least 0.5375, 0.14, 0.2 and 4.1 mg/gr dry weight (DW), respectively.
- a process for the large scale in vitro production of olive cell cultures does not include the extraction of the fruit cells.
- the produced fruit cell cultures, manufactured in accordance with the large scale process described herein were shown to include high amounts of polyphenols particularly, the secondary metabolites tyro sol, hydroxytyrosol, oleuropein and verbascoside.
- the unique composition of olive cells which, as an outcome of scale up process, includes a whole matrix of polyphenols and other healthy ingredients, naturally existing in OC of a plant, with higher concentration, i.e., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or higher, of olive polyphenols, including tyrosol, hydroxytyrosol, oleuropein and verbascoside, as described in table 5, which provides a summary of the values known from the literature.
- polyphenols refers to naturally occurring phyto organic compounds having more than one phenol group. Polyphenols may range from simple molecules, such as phenolic acid, to large, highly polymerized, compounds such as hydrolyzed tannins.
- the phenolic rings of polyphenols are typically conjugated to various sugar molecules, organic acids and/or lipids. Differences in this conjugated chemical structure account for the chemical classification and variation in the modes of action and health properties of the various polyphenol compounds.
- polyphenols include, but are not limited to, phenolics, terpenes and sterols.
- Typical olive polyphenols include, but are not limited to, phenolics, terpenes and sterols.
- the olive fruit may be of a wild or cultivated variety.
- the calli cells and/or suspension culture of olive cells is derived from one or more of olive fruit cross sections: olive pulp, olive seed, olive petiole or olive leaf.
- Some embodiments are directed to a composition comprising non-extracted, dry calli cells culture of olive fruit/leaf cells.
- the calli cells culture is grown in vitro.
- the cell culture comprises both primary and secondary metabolites.
- Some embodiments are directed to a method for the production of polyphenols from a culture of olive cells.
- the amount of materials, including polyphenols may vary in different batches of fruit
- the use of a culturing protocol for preparing the fruit/leaf cell cultures ensures the reproducibility of the preparation and its contents.
- various batches of fruit cells, prepared from the same culture have a typical HPLC fingerprint.
- the concentrations of the various materials in each batch may change; however, as mentioned above, if prepared from the same culture, the HPLC fingerprint is consistent for all batches.
- the relative amounts of the various polyphenols in the prepared olive fruit/leaf cells differ from the relative amounts thereof in the agricultural olive fruit, as shown in Table 5 in the Examples Section. According to some embodiments, the amount of certain polyphenols is amplified in the prepared fruit/leaf cells, in comparison to their amount in the agricultural olive fruit.
- the amount of the secondary metabolite hydroxytyrosol is more than about 0.14 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolite tyrosol is more than about 0.5375 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolite oleuropein is more than about 0.2 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolite verbascoside is more than about 4.1 mg/gr, after the olive cell cultures are dried to a powder
- the amount of the secondary metabolites tyrosol is between about 0.53-21.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 0.53-1.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 1.0-3.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 3.0-5.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites tyrosol is between about 5.0-7.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 7.0-9.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 9.0-11.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 11.0-13.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites tyrosol is between about 13.0-15.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 15.0-17.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 17.0-19.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 19.0-21.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites oleuropein is between about 0.2-10 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 0.2-1.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 1.0-2.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 2.0-3.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites oleuropein is between about 3.0-4.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 4.0-5.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 5.0-6.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 6.0-7.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites oleuropein is between about 7.0-8.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 8.0-9.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 9.0-10.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites verbascoside is between about 4.1-151.1 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 4.1-10.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 10.0-20.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 20.0-30.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites verbascoside is between about 30.0-40.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 40.0-50.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 50.0-60.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 60.0-70.0 mg/gr, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites verbascoside is between about 70.0-80.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 80.0-90.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 90.0-100.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 100.0-110.0 mg/g, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites verbascoside is between about 110.0-120.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 120.0-130.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 130.0-140.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 140.0-151.1 mg/g, after the olive cell cultures are dried to a powder.
- the amount of the secondary metabolites hydroxytyrosol, tyrosol, oleuropein and verbascoside in the olive cell cultures is between about 0.14-15.7, 0.53-21.0, 0.2-10, 4.1-151.1 mg/gr, respectively after the olive cell cultures are dried to a powder.
- the amount of total olive polyphenols including hydroxytyrosol, tyrosol, oleuropein and verbascoside is more than about 1 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 10 mg/gr after the olive cell cultures are dried to a powder According to some embodiments of the invention, the amount is more than about 15 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 25 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 50 mg/gr after the olive cell cultures are dried to a powder.
- the amount is more than about 100 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 150 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 200 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 250 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 300 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 350 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 400 mg/gr after the olive cell cultures are dried to a powder.
- the olive cell cultures prepared according to the large scale method of the invention contain less than about 10% w/v fat.
- Fat refers to any of a group of natural esters of glycerol and various fatty acids conjugated or free or any combination thereof.
- the olive cell cultures contain less than about 5% w/v fat. According to some embodiments, the olive cell cultures contain less than about 3% w/v fat. According to some embodiments, the olive cell cultures contain less than about 2% w/v fat. According to some embodiments, the olive cell cultures contain less than about 1% w/v fat. According to some embodiments, the olive cell cultures contain about 1% w/v fat, As used herein, fat refers to a fat types, e.g., saturated, monounsaturated and polyunsaturated. According to some embodiments, the olive cell cultures are dried, thus concentrating the materials found therein, including the fat. According to some embodiments, the materials are concentrated by a factor of about 5.
- the materials are concentrated by a factor of about 10. According to some embodiments, the materials are concentrated by a factor of about 15. According to some embodiments, the materials are concentrated by a factor of about 20. According to some embodiments, the materials are concentrated by a factor of about 25. According to some embodiments, the materials are concentrated by a factor of about 30.
- a process for the in vitro production of a cell culture of olive fruit/leaf cells grown comprising:
- a large scale process for the in vitro production of a cell culture of olive fruit/leaf cells grown comprising:
- At least one of the bioreactors is a disposable bioreactor.
- a “disposable bioreactor” it is meant a bioreactor with a disposable bag, which can be for a single use bag instead of a culture vessel.
- the disposable bag may be prepared from three or more layers of plastic foil.
- one layer is prepared from polyethylene, polyethylene terephthalate or LDPE to provide mechanical stability.
- a second layer may be prepared using nylon, PVA or PVC that acts as a gas barrier.
- a contact layer may be prepared from PVA or PP or another layer of polythyelene, polyethylene terephthalate or LDPE.
- the single-use materials that contact the product must be certified by the European Medicines Agency or similar authorities responsible for other regions.
- the disposable bioreactor is prepared from one or more layers of polyethylene.
- the disposable bioreactor is prepared from an inner and outer layer of polyethylene and a middle nylon layer.
- stirrers similarly to conventional bioreactors; however, the stirrers may be integrated into the plastic bag.
- the closed bag and the stirrer are pre-sterilized. In use the bag is mounted in the bioreactor and the stirrer is connected to a driver mechanically or magnetically.
- Other single-use bioreactors are agitated by a rocking motion.
- Other single-use bioreactors are airlift bioreactor in which the reaction medium is agitated and aerated by introduction of air. This type of bioreactor does not need any mechanical agitators inside the single-use bag.
- the large scale process for preparing olive cell cultures comprises a number of subsequent steps.
- the amount of olive cell cultures prepared in each step is either larger or not than that prepared in the previous step.
- the olive cell cultures prepared in each step may be inoculated or harvested to be used as a starter for the next step of the large scale process.
- the fruit cells are typically grown until they reach the plateau in their growth profile.
- a composition comprising a complex of pholyphenols including tyrosol, hydroxytyrosol, oleuropein and verbascoside, wherein the amount of verbacoside in respect to the other polyphenols is higher than 1:20.
- the ratio is higher than 1:10.
- the ratio is higher than 1:5.
- the ratio is higher than.
- the ratio is higher than 1:3.
- the ratio is higher than 1:2.
- the composition is derived from a natural source. According to some embodiments, the composition is derived from olive cell cultures grown in large scale disposable bioreactors. According to some embodiments, the composition is derived from olive cell cultures grown in large scale disposable bioreactors, according to the process described herein.
- the olive cells are grown in bioreactors.
- the bioreactors are designed so as to allow adequate mixing and mass transfer, while minimizing the intensity of shear stress and hydrodynamic pressure.
- at least one of the bioreactors is a disposable bioreactor. This can be the first bioreactor or the intermediate bioreactor or the last bioreactor or any combination thereof.
- the disposable bioreactor is the last bioreactor, such that after growing in the last bioreactor, the cells are harvested therefrom and dried, so as to form a powder.
- the first step includes the preparation of an olive cell culture in a flask, such as an Erlenmeyer or a bioreactor.
- the first step involves the preparation of up to 1.0 L of an olive cell culture.
- first step involves the preparation of up to 1.5 L of an olive cell culture.
- first step involves the preparation of up to 2.0 L of an olive cell culture.
- the first step is conducted using a glass, metal or plastic flask.
- the flask is disposable.
- the flask may be reused any number of times.
- the flask is sterilized by any appropriate means between uses.
- the first step includes the use of any appropriate medium for growing the olive cells.
- the medium used for growing the fruit cells includes cell growth medium, salts, vitamins, sugars, hormones or any combination thereof.
- the cell growth medium includes O-5, O-4, O-3, M-3medium (as defined in Table 1A) or any combination thereof.
- the cell growth medium is supplemented with sucrose, casein hydrolysate, myoinositol, 1-naphthaleneacetic acid (NAA), kinetin, 2,4,D, written already BA, 2iP, or any combination thereof.
- the cell growth medium is supplemented with about 1-6% sucrose, about 0.2-0.3 g/L casein hydrolysate, about 0.05-0.15 g/L myo inositol, about 0.05-0.15 mg/L NAA and/or about 0.1-0.3 mg/L kinetin.
- the pH of the medium is between about 4-6.
- the growth medium comprises salts such as magnesium, phosphate, nitrate or any combination thereof.
- the growth medium includes KNO 3 , MgSO 4 , NaH 2 PO 4 , or any combination thereof.
- the medium includes vitamins or any combination thereof.
- the medium includes sugars such as sucrose or any combination thereof.
- the concentration of the sucrose added to the growth medium is between 1 to 6%. In another embodiment, the concentration of the sucrose added to the growth medium is about 3%.
- casein, casein hydrolysate or casein peptone may be included in the cell growth medium.
- growth hormones may be included in the cell growth medium.
- the growth medium includes hormones. According to some embodiments the olive cells are grown without the addition of hormones.
- plant culture media examples include, but are not limited to: Anderson (Anderson, In Vitro 14:334, 1978; Anderson, Act. Hort., 112:13, 1980), Chee and Pool (Sci. Hort. 32:85, 1987), CLC/Ipomoea (CP) (Chee et al., J. Am. Soc. Hort. Sci. 117:663, 1992), Chu (N.sub.6) (Chu et al., Scientia Sinic. 18:659, 1975; Chu, Proc. Symp. Plant Tiss. Cult., Peking 43, 1978), DCR (Gupta and Durzan, Plant Cell Rep.
- the olive cells and the medium are continuously mixed during the first step. According to further embodiments, the olive cells and the medium are mixed occasionally during the first step. According to some embodiments, the temperature during the first step is between about 20° C. and 30° C. According to some embodiments, the temperature during the first step is between about 22° C. and 28° C. According to some embodiments, the temperature during the first step is about 25° C. According to some embodiments, the olive cells are grown in the first step for more than 3 days. According to some embodiments, the olive cells are grown in the first step for more than 5 days. According to some embodiments, the olive cells are grown in the first step for more than 3 days and less than 3 weeks.
- the bioreactor used in the process of the invention includes an inlet through which the olive cells from the previous step, the medium and any additional materials are placed into the bioreactor.
- the bioreactor used in the process of the invention includes an outlet for removing any materials desired.
- the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases.
- the gas outlet is operated manually.
- the gas outlet is operated automatically, wherein gases are let out of the flask once the atmosphere in the flask reaches a pre-defined pressure.
- the predefined pressure up to 8 PSI.
- the gas outlet is a separate entity from the outlet for removing liquids/solids.
- the olive cells are inoculated into a small scale bioreactor, which is termed here also the first bioreactor, for the second step of the large scale process.
- the small scale bioreactor is a 4 L reactor.
- the small scale bioreactor is a 3-5 L reactor.
- the small scale bioreactor is a 3-10 L reactor.
- the small scale bioreactor is a 4-8 L reactor.
- the small scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the small scale bioreactor is disposable. If the small scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- the production of secondary metabolites is known to be significantly reduced with increasing bioreactors volumes, in comparison to the amount of the same metabolites in small scale productions, using, e.g., glass flasks, such as Erlenmeyers.
- the large scale process detailed herein provides olive cells in which the amount of the secondary metabolites is not reduced when grown in bioreactors. Further, the production of certain secondary metabolites may even be amplified.
- the relative amounts of the secondary metabolites in olive cells grown in the small scale bioreactor are not significantly reduced in comparison to their relative amounts in the first step of the process.
- the components described above for use in the growth medium in the first step may be used also in the second step of the process.
- the growth medium used in the small scale bioreactor is the same as used in the first step of the large scale process.
- the relative amounts of the different components found in the growth medium in the second step is the same as in the first step.
- the relative amounts of the different components found in the growth medium in the second step differ from the relative amounts used in the first step.
- additional materials are added to the growth medium in the second step of the process.
- the small scale bioreactor includes an inlet through which the fruit cells from the first step, air, the medium and any additional materials are placed into the bioreactor.
- the small scale bioreactor includes an outlet for removing any materials desired.
- the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases.
- the gas outlet is operated manually.
- the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure.
- the predefined pressure is 8 PSI.
- the gas outlet is a separate entity from the outlet for removing liquids/solids.
- the olive cells and the medium are continuously mixed during the second step. According to further embodiments, the olive cells and the medium are mixed occasionally during the second step. According to some embodiments, the temperature during the second step is between about 20 to 30° C. According to some embodiments, the temperature during the second step is between about 22 to 28° C. According to some embodiments, the temperature during the second step is about 25° C. According to some embodiments, the olive cells are grown in the second step for more than a week and less than two weeks. According to some embodiments, the olive cells are grown in the second step for less than a week. In some embodiments of the invention, the olive cells are grown between 4-30 days before being inoculated into the next bioreactor.
- the harvested olive cells are placed into a medium scale bioreactor.
- the medium scale bioreactor is a 30-50 L reactor.
- the medium scale bioreactor is a 40-60 L reactor.
- the medium scale bioreactor is a 30-70 L reactor.
- the medium scale bioreactor is a 20-100 L reactor.
- the medium scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the medium bioreactor is disposable. If the medium scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- the relative amounts of the secondary metabolites in olive cells grown in the medium scale bioreactor are not significantly reduced in comparison to their relative amounts in any of the previous steps of the process.
- the components described above for use in the growth medium in any of the previous steps may be used also in the third step of the process.
- the growth medium used in the medium scale bioreactor is the same as used in any of the previous steps of the medium scale process.
- the relative amounts of the different components found in the growth medium in the third step is the same as in any of the previous steps of the process.
- the relative amounts of the different components found in the growth medium in the third step differs from the relative amounts used in any of the previous steps of the process.
- additional materials are added to the growth medium in the third step of the process.
- the medium scale bioreactor includes an inlet through which the olive cells from the second step, the medium, air and any additional materials are placed into the bioreactor.
- the medium scale bioreactor includes an outlet for removing any materials desired.
- the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases.
- the gas outlet is operated manually.
- the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure.
- the predefined pressure is up to 8 PSI.
- the gas outlet is a separate entity from the outlet for liquids/solids.
- the olive cells and the medium are continuously mixed during the third step. According to further embodiments, the olive cells and the medium are mixed occasionally during the third step. According to some embodiments, the temperature during the third step is between about 20 and 30° C. According to some embodiments, the temperature during the third step is between about 22 and 28° C. According to some embodiments, the temperature during the third step is about 25° C. According to some embodiments, the olive cells are grown in the third step for about two to three weeks. According to some embodiments, the olive cells are grown in the third step for less than one week. According to some embodiments, the olive cells are grown in the third step for about one to two weeks. According to some embodiments, the olive cells are grown in the third step for about three to five weeks. According to some embodiments, the olive cells are grown in the third step for about 5 to 30 days.
- the olive cells may be inoculated from the medium scale bioreactor typically by any appropriate means.
- the harvested olive cells are placed into a larger scale bioreactor.
- the larger scale bioreactor is a 1000 L reactor.
- the larger scale bioreactor is a 200-500 L reactor.
- the large scale bioreactor is a 500-1000 L reactor.
- the large scale bioreactor is a 1000-1500 L reactor.
- the large scale bioreactor is a 500-1100 L reactor.
- the larger scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the larger scale bioreactor is disposable. If the larger scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- the relative amounts of the secondary metabolites in olive cells grown in the larger scale bioreactor are not significantly reduced in comparison to their relative amounts in the previous steps of the process.
- the components described above for use in the growth medium in any of the previous steps may be used also in the fourth step of the process.
- the growth medium used in the larger scale bioreactor is the same as used in any of the previous steps.
- the relative amounts of the different components found in the growth medium in the fourth step is the same as in any of the previous steps.
- the relative amounts of the different components found in the growth medium in the fourth step differs from the relative amounts used in any of the previous steps.
- additional materials are added to the growth medium in the fourth step of the process.
- the larger scale bioreactor includes an inlet through which the olive cells from the third or second step, the medium and any additional materials are placed into the bioreactor.
- the larger scale bioreactor includes an outlet for removing any materials desired.
- the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases.
- the gas outlet is operated manually.
- the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure.
- the predefined pressure is up to 8 PSI.
- the gas outlet is a separate entity from the outlet for liquids/solids.
- the bioreactor may include two or more inlets and/or outlets.
- Each inlet and/or outlet may be designated for the passage of a certain type of material or otherwise, various materials may pass through the same inlet/outlet. The various materials may pass through the inlet/outlet together or separately from one another.
- Any bioreactor related to herein may further include two or more inlets/outlets designated for the passage of at least one type of material.
- the olive cells and the medium are continuously mixed during the fourth step. According to further embodiments, the olive cells and the medium are mixed occasionally during the fourth step. According to some embodiments, the temperature during the fourth step is between about 20 to 30° C. According to some embodiments, the temperature during the fourth step is between about 22 to 28° C. According to some embodiments, the temperature during the fourth step is about 25° C. According to some embodiments, the olive cells are grown in the third or fourth step until they reached a cell biomass of 10% to 70% w/w of the entire mass of the medium.
- the large scale process is terminated after the olive cells are grown in the larger scale bioreactor.
- the olive cells are grown in the larger scale bioreactor until they reach a cell biomass of 10% to 70% w/w. Once the cell biomass of 10% to 70% w/w is reached, the olive cells are harvested from the large scale bioreactor by any appropriate means and are further processed.
- the olive cells are further processed by ant appropriate type of drying, lyophilization, Freeze-Drying, fluidized bed air drying and Spray Drying. According to some embodiments, the processing of the olive cells does not include the extraction of active ingredients therefrom.
- the large scale process may include one step of inoculating the cells from a flask into a bioreactor, which can be in any size, and harvesting the cells.
- the olive cells may be inoculated in a series of bioreactors wherein each of the bioreactors is typically larger than the previous bioreactor used. Any number of additional steps is performed according to the large scale process. The additional steps include possible intermediate steps in which the cells are harvested or inoculated and placed in a larger bioreactor and grown there until being harvested or inoculated and transferred to a larger bioreactor.
- the process includes additional steps for growing the olive cells harvested from the large scale bioreactor.
- a pharmaceutical or nutraceutical composition or a food additive comprising the olive cells manufactured in the large scale process of the invention.
- the pharmaceutical or nutraceutical composition or a food additive may be administered to the subject by oral administration.
- composition refers to a preparation of olive cell culture, as further described hereinabove, with or without other chemical components, such as physiologically suitable carriers and excipients.
- Olive polyphenols were shown to have beneficial effects on learning and memory deficits found in ageing and diseases, such as those related to the overproduction of amyloid-beta peptide.
- olive polyphenols were shown to influence gut microbial balance by promoting growth of bacteria influencing lipid metabolism and inhibition of pathogenic bacteria, as well as increase bone density.
- the method comprises administering to a subject in need a pharmaceutical or nutraceutical composition or a food additive comprising the olive cell culture, wherein the culture is possibly manufactured according to the large scale process detailed herein and is possibly rich in secondary metabolites.
- treating refers to the prevention of some or all of the symptoms associated with an inflammatory disease, a condition or disorder.
- the term “treating” also refers to alleviating the symptoms or underlying cause of an inflammatory disease, prolongation of life expectancy of patients having a disease, as well as complete recovery from a disease.
- Metabolic abnormalities are associated with obesity, insulin resistance glucose intolerance, type II diabetes mellitus (DMII), dyslipidemia fatty liver, steatohepatitis, and steatosis. These abnormalities increase the risk of stroke cardio-vascular diseases.
- the etiology of the metabolic syndrome is considered to be multifactorial involving genetic and environmental effects.
- Metabolic syndrome also known as “the deadly quartet” or “Syndrome X” or the “Insulin Resistance Syndrome” is a cluster of risk factors for various diseases, such as cardio-vascular diseases, stroke and diabetes mellitus type II, i.e. insulin resistance, hyperinsulinemia, abdominal obesity, (caused by an accumulation of intra-abdominal fat), elevated serum lipids, and high blood pressure. 25% of adults living in the United States are diagnosed with metabolic syndrome. It is believed that the pathophysiology of the metabolic syndrome is related to insulin resistance.
- diseases such as cardio-vascular diseases, stroke and diabetes mellitus type II, i.e. insulin resistance, hyperinsulinemia, abdominal obesity, (caused by an accumulation of intra-abdominal fat), elevated serum lipids, and high blood pressure. 25% of adults living in the United States are diagnosed with metabolic syndrome. It is believed that the pathophysiology of the metabolic syndrome is related to insulin resistance.
- the risk factors include the following: elevated waist circumference ( ⁇ 102 cm in man and 88 cm in women); elevated triglycerides (>150 mg/dL); reduced high-density lipoprotein (HDL) cholesterol ( ⁇ 40 mg/dL in men and 50 mg/dL in women); elevated blood pressure (>130/85 mm Hg) and elevated fasting glucose (>100 mg/dL.
- elevated waist circumference ⁇ 102 cm in man and 88 cm in women
- elevated triglycerides >150 mg/dL
- HDL high-density lipoprotein
- HDL high-density lipoprotein
- elevated fasting glucose >100 mg/dL.
- Other risk factors may contribute to the metabolic syndrome as well. Additionally, the risk factors may vary in different populations.
- Olive cell culture was initiated from olive fruits ( Olea europaea L.) of Nabali, Manzanilla, Souri and Barnea cultivars, including all leaves, petioles, fruits and kernels.
- Olive plant parts young leaves and their petriols, immature fruits (about 6 weeks from flowering) and kernels from immature olives were rinsed under running water and sterilized by agitation in 70% ethanol for three minutes and then 3% Na-hypochlorite solution for 20 minutes, followed by three washes in sterile water. Plant parts were dried under sterile conditions and further dissected into ⁇ 0.5 cm sections.
- Olive plant explants were plated on MS Murashige and Skoog medium basal medium (Table 1B) supplemented with sucrose and various combinations of the auxines 2,4-dichlorophenoxyacetic acid (2,4-D), 1-naphthaleneacetic acid (NAA) and the cytokinines kinetin, 6-( ⁇ , ⁇ -Dimethylallylamino)purine (2iP) and benzyladenine (BA) at various concentrations.
- One medium composition (O-2) included active charcoal. The pH of the medium was 5.8.
- the medium was solidified with agar (Gelrite, Duchefa or Phytagel, Sigma). Plate compositions are specified in Table 1A. Plates were kept at 25° C. in the dark. When formed calli reached a diameter of 1 cm, they were split in a 1:3 ratio onto a similar medium. Calli were transferred to fresh plates every 4 weeks.
- the suspension cultures maintained stable growth in suspension (50 to 1000 ml Erlenmeyer flasks). Cultures were routinely subcultured every 7-20 days to fresh growth media.
- Olive cells were grown in suspension under continuous fluorescent light (1000 1 ⁇ ) at 25+5° C., in 1 liter Erlenmeyer flasks on an orbital shaker.
- the cultured olive cells grown in liquid medium were filtered through filter and dried by lyophilization or spray dryer
- Olive tissues (fruits and leaves) were crushed under liquid nitrogen and extracted as described above, the extract was analyzed by HPLC and used as a reference for olive polyphenols content.
- Olive calli extract was analyzed by LC-MS. The method is described in: Food Chemistry 138 (2013) 1381-1391.
- Olive calli samples were extracted in methanol (400 ⁇ l/1 gr of calli's fresh weight), as described above.
- the content of olive polyphenols was determined as follows: hydroxytyrosol, oleuropein and pinoresinol were detected at 280 nm. Tyrosol was detected at 275 nm and verbascoside was detected at 330 nm. Total polyphenols were monitored at 280 nm using commercial Epicatechin (Sigma) as a standard, and expressed as ⁇ g epicatechin equivalent.
- Polyphenolic compounds in olive-derived cultures were characterized and quantitated by high performance liquid chromatography (HPLC) analysis. Selected phenolic compounds were identified by their UV absorbance spectra and retention times. Their concentrations were determined by means of a calibration curve using different external standards. Analysis was performed by JASCO PU-2089 HPLC system using the operation software ChromNAV. Total polyphenols were determined by summing AUC of peaks as monitored at 280 nm, and quantified, based on epicatechin as a standard. Total polyphenols is expressed as epicatechin equivalents. Hydroxytyrosol, Oleuropein and pinoresinol were analyzed based on characteristic absorption at 280 nm. Similarly, tyrosol was detected at 275 nm and verbascoside was detected at 330 nm. Compounds were quantified according to standard curves of commercial standards, respectively.
- LC-MS analysis of the sample was performed using an Accela LC system coupled with an LTQ Orbitrap Discovery hybrid FT mass spectrometer (Thermo Fisher Scientific Inc.) equipped with an electrospray ionization source.
- the mass spectrometer was operated in a negative ionization mode, wherein the ion source parameters were as follows: spray voltage 3.5 kV, capillary temperature 300° C., and ion-transfer optics parameters were optimized using automatic tune option, sheath gas rate (arb) 35, and auxiliary gas rate (arb) 15.
- Mass spectra were acquired in the m/z 150-2000 Da range.
- the LC-MS analysis was performed in data depending acquisition mode.
- the LC-MS system was controlled and the data were analyzed using Xcalibur software (Thermo Fisher Scientific Inc). Chromatographic separation was achieved on Kinetex Hexyl-Phenyl column (2.6 ⁇ m, 150 ⁇ 2.1 mm, Phenomenex) using an ACN/Water +0.1% AcOH (in both) gradient.
- Hydroxytirosol content in various olive calli cultures ranged from 0.281 to 1.963 ⁇ g/mg of dry-weight (DW).
- Tyrosol content ranged from 1.075 to 4.191 ⁇ g/mg of DW.
- Oleuropein content ranged from 2-10 ⁇ g/mg (DW).
- Verbascoside content ranged from 8.212 to 37.78 ⁇ g/mg DW, and pinoresinol was detected only in callus of Nabali cv. Origin, at 0.09 ⁇ g/mg DW, considering a drying factor of 20.
- Table 5 The content of these compounds in different parts of olive plant as compared to olive calli as well as in cell suspension cultures and bioreactors is summarized in Table 5.
- the concentrations of active compounds found in olive calli are within the range of these compounds in green olives (Alagna et al., 2012, phenol explorer database). Moreover, the production of high verbascoside concentrations characterizes early maturation stages of olive fruit, and was not shown in calli generated by others, whereas the verbascoside expression in the calli presented here and prepared according to this invention, is stable and is not limited to any development stage.
- Stage 1 cells are prepared and grown as described in example 1.
- Small scale bioreactor culturing is performed by inoculating a 7 to 16 old day cell suspensions grown in the Erlenmeyer of Stage 1 into a 4-8 liter disposable bioreactor at 25 +5° C.
- the cells were grown in the suspension under continuous fluorescent light (1000 1 ⁇ ) in a growing medium containing modified MS supplemented with sucrose 1-6% and the Kinetin, 2,4,D, NAA, BA, 2iP and casein hydrolysate or a combination thereof
- the cell suspensions grown in a small scale biorcactor were inoculated into a 30-50 liter disposable bioreactor.
- the cells were grown in a suspension under continuous fluorescent light (1000 1 ⁇ ) at 25+5° C.
- the cell suspension grown in the small or large scale bioreactor is inoculated into a 300-1000 liter disposable bioreactor.
- the cells were grown in a suspension under continuous fluorescent light (1000 1 ⁇ ) at 25+5° C.
- the growing medium contained modified MS supplemented with sucrose 1-6% and the Kinetin, 2,4,D, NAA, BA, 2iP and casein hydrolysate or a combination thereof
- the cells were harvested once they reached a cell biomass of 10% to 70% (w ⁇ v).
- the harvested cells were dried (in a spray dryer or lyophilized) to produce a fine green powder, with a typical composition, taste and odor.
- Olive Cells were grown in an Erlenmeyer shake flask in different medium compositions: O4 (modified MS supplemented with sugar hormones), and Gamborg B5. The results are presented in Table 7, demonstrating that olive cells grown in O4 produce approximately 1.9 higher biomass than cells grown in Gamborg B5 medium.
- Olive cells were grown in large bioreactors in different medium compositions: O4 (modified MS) and Gamborg B5. The results, obtained on day 5, are presented in Table 8. The results in Table 8 demonstrate that cells grown in the O4 medium produces three olive polyphenols, i.e., tyrosol, hydroxytyrosol, and oleorupein, which are not detected in the olive cells grown in Gamborg B5.
- Table 8 further shows that olive cells grown in O-4 medium produce approximately 2.65 higher verbascoside levels than olive cells grown in the Gamborg B5 medium.
- Olive Cells were grown in O-4 medium, namely modified MS medium with additional agents defined as O-4, in disposable large bioreactors. The results reveal that cells undergo exponential growth yielding a 200 gr/; fresh biomass at day 10 ( FIG. 2 ). It is noted that these cells continue to grow, and can reach higher biomasses than presented.
- the production of secondary metabolites including polyphenols, such as tyrosol and verbascoside, is expected to be significantly reduced when larger quantities of olive cells are grown in bioreactors, in comparison to the amount of the same metabolites in small scale productions, using, e.g., glass flasks, such as Erlenmeyers.
- the large scale process detailed herein provides olive cells in which the amount of the secondary metabolites is not reduced when grown in bioreactors. Further, the production of certain secondary metabolites may even be amplified.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application further describes a composition in a form of a powder comprising olive fruit/leaf cells grown in vitro and a method of treating metabolic syndrome disorders, such as, high cholesterol level, comprising administering an effective amount of the composition. The cell line callus culture of olive cells manufactured according to the process of the invention includes high level of hydroxytyrosoll, tyrosol, oleoropein and verbascoside.
Description
- This application is a continuation of Ser. No. 16/072,886 filed Jul. 26, 2018, which is a NP application of PCT/IL2017/050098 filed Jan. 26, 2017, which claims priority to U.S. 62/287,453 filed Jan. 27, 2016. The contents of these applications are incorporated into this application in their entirety.
- The invention is directed to olive derived cell cultures, a process for the large scale production of such cell cultures, as well as methods of using the same.
- Large scale processes are known in the art and are necessary for the industrial production of various materials. Since large scale processes cannot be performed by the same means as small scale processes, specific processes for the large scale production of materials must be designed, even if small scale processes exist.
- Nutraceuticals are sometimes prepared using synthetic processes that provide the desired active ingredients, e.g., polyphenols, which are naturally found in fruit cells. However, the use of synthetic processes does not provide the natural ingredients along with the active ingredients, which sometimes contribute to the efficiency of the formulation.
- Other types of nutraceuticals are prepared from the natural plants; however, all known large scale processes for preparing nutraceuticals from plants include the extraction of the prepared plant cells in order to obtain the desired active ingredient. However, when plants containing polyphenols, for example, are extracted, the final product may be bitter. Also, only certain parts of the plant may be successfully extracted since only they contain the desired amounts of the active ingredients.
- Small scale processes for the preparation of fruit cells are known in the art; however, large scale processes are more difficult to design since they tend to amplify the production of the primary metabolites, while minimizing the productions of the secondary metabolites. Since active ingredients, such as polyphenols, are secondary metabolites their production in large-scale processes is complex.
- Nutraceuticals derived from polyphenol-containing fruit extracts are known for their beneficial effects. However, it has been shown that the therapeutic effect of fruit extracts is dependent on species, location, year (annual climate), processing etc. and therefore reliance on natural fruits as a source of these regulatory compounds does not lead to a homogeneous or consistent supply of material. Furthermore, fruits are often contaminated by residual fungicides, pathogens, pesticides and pollutants.
- Nonetheless, dietary consumption of polyphenols was shown to be inversely related to morbidity and mortality from coronary heart disease (CHD). Moreover, an inverse association between polyphenols intake and subsequent occurrence of ischemic heart disease, or cerebrovascular disease was shown. Over the last decade, studies indicated that olive polyphenolic compounds have potent antioxidant properties and their therapeutic properties further include anti-inflammatory and anti-microbial activities, treatment and prevention of cardiovascular disease, promotion of healthy lifestyle in the context of prevention of cancer and age-related processes such as Alzheimer's disease (Farr et al,. J. Alzheim. Dis. 2012, 28, 81-92, Luccarini et al., Neurobiology of Aging 2014 1-16). Another potential application is the effect of olive polyphenols on gut microbial balance, affecting lipid metabolism. Other potential applications include the effect on obesity-related gene expression (Martin et al. Mol. Nutr. Food Res. 2013, 00, 1-12).
- Thus, there is a need in the art for a large scale process for preparing plant cells from natural ingredients, which includes the production of both the primary and the secondary metabolites of the plant cells. There is need for natural (phyto) compositions that may be prepared in a large scale process in which the amount of the active ingredient is consistent and recurrent (e.g., clonal preparations), is highly bioavailable and easily administered for the treatment and prevention of various diseases and disorders.
- Olive products, Olive oil, table olives and fruits extracts, as well as plant parts, such as leaves, exhibit potent biological properties attributable to the presence of polyphenols. Polyphenols content of olive fruits contain primarily phenolics, terpenes and sterols, all of which are present in various plant parts, such as, bark, leaf and fruit. The major phenolic compounds are oleuropein, demethyloleuropein, 3-4 DHPEA-EDA, ligstroside, tyrosol, hydroxytyrosol, verbascoside and lignans (Alagna et al. BMC Plant Biology 2012, 12:162).
- Tyrosol, hydroxytyrosol, oleuropein and verbascoside are all known for their potent antioxidant capacity. These compounds are the major polyphenols in olive, and are responsible for the high antioxidant activity of olives and olive oil.
- Due to the extensive knowledge about the olive's health attributes and increasing public awareness about functional food, the demand for olive byproduct has increased tremendously in the western world. As a result of this trend, the extent of olive growth was increased significantly in many regions throughout the world, and industries that produced olive products have been developed.
- Thus, there is a need in the art for a large scale process for preparing olive plant cells, which includes both the primary and the secondary metabolites of olive plant cells. There is further a need for olive plant cells compositions that may be prepared in a large scale process in which the amount of the active ingredient/s is similar or higher than in olive plants, including the leaves. Further, compositions prepared in a large scale process would prove to be and be consistent and recurrent (e.g., clonal preparations) and therefore, would be advantageous over olive secondary metabolites obtained by other methods.
- Embodiments of the invention are directed to a large scale process for the in vitro production of an olive cell culture of olive cells grown comprising: growing olive cells in a flask;
- inoculating the olive cells from the flask into a first bioreactor;
- inoculating the olive cells from the first bioreactor into a second bioreactor;
- optionally inoculating the olive cells from the second bioreactor into a last bioreactor; and
- harvesting the olive cells from the last bioreactor;
- wherein the second bioreactor is a last bioreactor or an intermediate bioreactor and wherein the olive cells harvested from the last bioreactor are dried.
- According to some embodiments, the size of each bioreactor used in the process is larger than the one in which the olive cells were previously grown.
- According to some embodiments, if the second bioreactor is an intermediate bioreactor, an additional step of inoculating the olive cells to another intermediate bioreactor or to the last bioreactor is performed.
- According to some embodiments, the large scale process of the invention further includes additional steps of inoculating the olive cells from the second bioreactor into any number of sequential intermediate bioreactors.
- According to some embodiments, any one of the bioreactors is a 4-10 liter bioreactor. According to some embodiments, any one of the bioreactors is a 10-50 liter bioreactor. According to some embodiments, any one of the bioreactors is a 50-200 liter bioreactor. According to some embodiments, any one of the bioreactors is a 200-500 liter bioreactor. According to some embodiments, any one of the bioreactors is a 200-1000 liter bioreactor.
- According to some embodiments, the olive cells are grown in bioreactors comprising a growth MS medium as defined in Table 1B supplemented with different hormones and various sucrose concentrations e.g.
- M-3, O-3, O-4, O-5, as defined in Table 1A, or any combination thereof.
- According to some embodiments, the olive cells are grown in bioreactors comprising a growth MS medium comprising one or more of kinetin, sucrose, 2,4,D, NAA, 2iP, BA or any combination thereof.
- According to some embodiments, the olive cells are grown in bioreactors comprising a growth MS medium comprising agar and one or more of kinetin, sucrose, 2,4,D, NAA, 2iP, BA or any combination thereof.
- The composition of each or those media, which in essence is a modification of the MS medium, is as detailed in the table below:
-
TABLE 1A Media composition of various MS plates used for olive calli M-3 0-1 0-2 0-3 0-4 0-5 MS (g/L)* 4.4 (**Full 4.4 (**Full 4.4 (**Full 2.2 (***Half 4.4 (***Full 2.2 (***Half strength) strength) strength) strength) strength) strength) Kinetin (mg/L) 0.5 2,4,D (mg/L) 0.5 1.3 2.6 0.1 0.5 NAA (mg/L) 2 BA(mg/L) 0.06 0.12 2iP (mg/L) 0.1 0.5 Sucrose (g/L) 40 30 30 20 45 30 Charcoal (g/L) 0.25 Agar (g/L) 6 6 6 6 6 6 *Olive cultures are grown on modified MS-Murashige and Skoog medium (Toshio Murashige and Folke K). Skoog medium supplemented with different hormones and various sucrose concentrations. **Full strength MS medium refers to 4.4 gr/L amount of MS powder added to the final medium ***Half strength MS medium refers to 2.2 gr/L amount of MS powder added to the final medium. - The composition of the MS medium is as follows:
-
TABLE 1B MS-Murashige and Skoog medium Composition Concentrations mg/L Elements Min Max CoCl2•6H2O 0.0063 0.05 CuSO4•5H2O 0.0063 0.05 FeNaEDTA 9.18 73.4 H3BO3 1.55 12.4 KI 0.21 1.66 MnSO4•H2O 4.23 33.8 Na2MoO4•2H2O 0.06 0.50 ZnSO4•7H2O 2.15 17.2 CaCl2 83.0 664.0 KH2PO4 42.5 340.0 KNO3 475 3800 MgSO4 45.1 361.1 NH4NO3 412.5 3300 Glycine 0.5 4.0 Myo-Inositol 25 200 Nicotinic acid 0.13 1.0 Pyridoxine HCl 0.13 1.0 Thiamine HCl 0.03 0.2 - Thus, according to some embodiments, the olive calli cells are grown in modified MS medium. According to some embodiments, the modified MS medium comprises:
- a) (M-3) 1.1-8.8 gr/L MS medium, 0.5 mg/L kinetin, 0.5 mg/
L - b) (O-1) 1.1-8.8 gr/L MS medium, 1.3 mg/
L - c) (O-2) 1.1-8.8 gr/L MS medium, 2.6 mg/
L - d) (O-3) 1.1-8.8 gr/L MS medium, 0.1 mg/
L - e) (O-4) 1.1-8.8 gr/L MS medium, 0.5 mg/
L - f) (O-5) 1.1-8.8 gr/L MS medium, 2.0 mg/L NAA, 0.5 mg/L 2iP, 30 gr/L sucrose, and 6 gr/L agar.
- Thus, according to some embodiments, the olive cells growing in vitro suspension are grown in modified MS medium. According to some embodiments, the modified MS medium that can be used for the suspension are same as those described for the growth of the olive calli but do not comprise agar:
- a) (M-3) 1.1-8.8 gr/L MS medium, 0.5 mg/L kinetin, 0.5 mg/
L - b) (O-1) 1.1-8.8 gr/L MS medium, 1.3 mg/
L - c) (O-2) 1.1-8.8 gr/L MS medium, 2.6 mg/
L - d) (O-3) 1.1-8.8 gr/L MS medium, 0.1 mg/
L - e) (O-4) 1.1-8.8 gr/L MS medium, 0.5 mg/
L - f) (O-5) 1.1-8.8 gr/L MS medium, 2.0 mg/L NAA, 0.5 mg/L 2iP and 30 gr/L sucrose.
- Thus, according to some embodiments, the olive calli cells are grown in modified MS medium. According to some embodiments, the modified MS medium comprises:
- a) 1.1-8.8 gr/L MS medium, kinetin, 2,4,D, sucrose and agar;
- b) 1.1-8.8 gr/L MS medium, 2,4,D, BA, sucrose and agar;
- c) 1.1-8.8 gr/L MS medium, 2,4,D, BA, sucrose, charcoal, and agar;
- d) 1.1-8.8 gr/L MS medium, 2,4,D, sucrose, and agar;
- e) 1.1-8.8 gr/L MS medium, 2,4,D, 2iP, sucrose, and agar; or
- f) 1.1-8.8 gr/L MS medium, NAA, 2iP, sucrose, and agar.
- Thus, according to some embodiments, the olive cells growing in suspension are grown in modified MS medium. According to some embodiments, the modified MS medium comprises:
- a) 1.1-8.8 gr/L MS medium, kinetin, 2,4,D, and sucrose;
- b) 1.1-8.8 gr/L MS medium, 2,4,D, BA, and sucrose;
- c) 1.1-8.8 gr/L MS medium, 2,4,D, BA and sucrose;
- d) 1.1-8.8 gr/L MS medium, 2,4,D and sucrose;
- e) 1.1-8.8 gr/L MS medium, 2,4,D, 2iP and sucrose; or
- f) 1.1-8.8 gr/L MS medium, NAA, 2iP and sucrose.
- According to further embodiments, the growth medium is enriched with sucrose, casein hydrolysate, myo inositol, 1-naphthaleneacetic acid (NAA), kinetin, 2,4,D (2,4-Dichlorophenoxyacetic acid), BA (benzyladenine), 2iP (6-dimethylamino purine), or any combination thereof. According to some embodiments, the growth medium does not include plant hormones. According to other embodiments, the growth medium includes plant hormones. According to some embodiments, the growth medium is enriched with 1-6% sucrose.
- According to some embodiments, at least one of the bioreactors is disposable. According to some embodiments, the disposable bioreactor is made from one or more layers of polyethylene. According to some embodiments, the disposable bioreactor includes an inner and an outer layer prepared from polyethylene and a middle layer prepared from nylon.
- Further embodiments of the invention are directed to a composition in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of section: olive pulp, olive seed, olive petiole or olive leaf.
- According to some embodiments, the olive fruit cells include polyphenols, such as, hydroxytyrosol, tyrosol, oleuropein, verbascoside and pinoresinol, but not limited only to these types. According to some embodiments, the olive fruit cells prepared include polyphenols selected from hydroxytyrosol, tyrosol, oleuropein, verbascoside and pinoresinol.
- According to some embodiments, the olive cells grown in vitro in a large scale process. According to some embodiments, the olive fruit cells are prepared according to the large scale process of the invention, as detailed herein.
- Further embodiments of the invention are directed to a method of treating inflammation comprising administering an effective amount of a composition comprising a powder comprising olive fruit cells grown in vitro, whereby the olive cells are derived from one or more of olive skin, olive lamellae and olive seeds. According to some embodiments, the olive cells used in the method are prepared according to the large scale process of the invention, as detailed herein.
- Additional embodiments of the invention are directed to olive calli culture comprising verbasco side in the amount of at least 8.2 μg/mg dry weight.
- In an embodiment of the invention, there is provided calli culture grown in vitro for the in vitro production of an olive cell culture of olive cells wherein the olive cell comprise Olive's polyphenols and high amount, e.g. more than 8.2 μg/mg DW, of verbascoside.
- Further, there is provided a large scale process for the in vitro production of an olive cell culture of olive cells grown comprising:
- growing olive cells in a flask;
- inoculating the olive cells from the flask into a first bioreactor;
- inoculating the olive cells from the first bioreactor into a second bioreactor; and
- harvesting the olive cells from the last bioreactor;
- wherein the second bioreactor is a last bioreactor or an intermediate bioreactor and wherein at least one of the first and the second bioreactor is disposable and wherein the olive cells harvested from the last bioreactor are dried.
- In some embodiments, the invention provides a composition in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of section: olive pulp, olive seed, olive petiole or olive leaf.
- In further embodiments, the invention provides a method of prevention and/or treatment of risk factors for cardiovascular disease, development of atherosclerotic plaque, protection of LDL particles from oxidative damage, maintenance of normal blood HDL-cholesterol concentrations, decrease of high blood pressure and to maintain normal haemostatic function. Olive polyphenols were shown to have beneficial effects on learning and memory deficits found in ageing and diseases, such as those related to the overproduction of amyloid-beta peptide. In addition, olive polyphenols were shown to influence gut microbial balance by promoting growth of bacteria influencing lipid metabolism and inhibition of pathogenic bacteria. The method comprising administering an effective amount of a composition comprising composition in a form of a powder comprising olive fruit/leaf cells grown in vitro, whereby the olive cells are derived from one or more of cross section, olive pulp, olive seed, olive petiole or olive leaf.
- In some embodiments, the olive cells culture is grown in vitro under dark conditions.
- In some embodiments, the olive cells culture is grown in vitro under fully dark conditions (24 hours a day).
- The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanied drawings. Embodiments of the invention are illustrated by way of example and not limitation in the figures of the accompanying drawings, in which like reference numerals indicate corresponding, analogous or similar elements, and in which:
-
FIG. 1 presents an HPLC chromatogram at 280 nm of olive polyphenols derived from olive cells grown in O4 medium (modified MS medium); and -
FIG. 2 presents olive cell growth in large bioreactors in O4 medium (modified MS medium). - In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure the present invention.
- Embodiments of the invention are directed to a composition in a form of a powder comprising a cell culture of olive cell culture (OC) grown in vitro in, whereby the cell culture of OC is derived from one or more of olive sections: olive pulp, olive seed, olive petiole or olive leaf. In an embodiment of the invention, the cell culture of OC includes tyrosol, hydroxytyrosol, oleuropein and verbascoside in an amount of at least 0.5375, 0.14, 0.2 and 4.1 mg/gr dry weight (DW), respectively.
- According to some embodiments, there is provided a process for the large scale in vitro production of olive cell cultures. In some embodiments of the invention, the process does not include the extraction of the fruit cells. Surprisingly, the produced fruit cell cultures, manufactured in accordance with the large scale process described herein, were shown to include high amounts of polyphenols particularly, the secondary metabolites tyro sol, hydroxytyrosol, oleuropein and verbascoside. The unique composition of olive cells (OC), which, as an outcome of scale up process, includes a whole matrix of polyphenols and other healthy ingredients, naturally existing in OC of a plant, with higher concentration, i.e., at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or higher, of olive polyphenols, including tyrosol, hydroxytyrosol, oleuropein and verbascoside, as described in table 5, which provides a summary of the values known from the literature. As used herein the term “polyphenols” refers to naturally occurring phyto organic compounds having more than one phenol group. Polyphenols may range from simple molecules, such as phenolic acid, to large, highly polymerized, compounds such as hydrolyzed tannins. The phenolic rings of polyphenols are typically conjugated to various sugar molecules, organic acids and/or lipids. Differences in this conjugated chemical structure account for the chemical classification and variation in the modes of action and health properties of the various polyphenol compounds. Examples of polyphenols include, but are not limited to, phenolics, terpenes and sterols. Typical olive polyphenols include, but are not limited to, phenolics, terpenes and sterols. The olive fruit may be of a wild or cultivated variety.
- According to some embodiments, the calli cells and/or suspension culture of olive cells is derived from one or more of olive fruit cross sections: olive pulp, olive seed, olive petiole or olive leaf.
- Some embodiments are directed to a composition comprising non-extracted, dry calli cells culture of olive fruit/leaf cells. According to some embodiments, the calli cells culture is grown in vitro. According to some embodiments, the cell culture comprises both primary and secondary metabolites.
- Some embodiments are directed to a method for the production of polyphenols from a culture of olive cells. According to some embodiments of the invention, although the amount of materials, including polyphenols, may vary in different batches of fruit, the use of a culturing protocol for preparing the fruit/leaf cell cultures ensures the reproducibility of the preparation and its contents. Thus, various batches of fruit cells, prepared from the same culture have a typical HPLC fingerprint. According to some embodiments, the concentrations of the various materials in each batch may change; however, as mentioned above, if prepared from the same culture, the HPLC fingerprint is consistent for all batches.
- According to some embodiments, the relative amounts of the various polyphenols in the prepared olive fruit/leaf cells differ from the relative amounts thereof in the agricultural olive fruit, as shown in Table 5 in the Examples Section. According to some embodiments, the amount of certain polyphenols is amplified in the prepared fruit/leaf cells, in comparison to their amount in the agricultural olive fruit.
- According to some embodiments, the amount of the secondary metabolite hydroxytyrosol is more than about 0.14 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolite tyrosol is more than about 0.5375 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolite oleuropein is more than about 0.2 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolite verbascoside is more than about 4.1 mg/gr, after the olive cell cultures are dried to a powder
- According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 0.14-15.7 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 0.14-1.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 1.0-2.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 2.0-3.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 3.0-4.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 4.0-5.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 5.0-6.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 6.0-7.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 7.0-8.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 8.0-9.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 90-10.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 10.0-11.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 11.0-12.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 12.0-13.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 13.0-14.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolite hydroxytyrosol between about 14.0-15.7 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolites tyrosol is between about 0.53-21.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 0.53-1.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 1.0-3.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 3.0-5.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 5.0-7.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 7.0-9.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 9.0-11.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 11.0-13.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 13.0-15.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 15.0-17.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 17.0-19.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites tyrosol is between about 19.0-21.0 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolites oleuropein is between about 0.2-10 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 0.2-1.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 1.0-2.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 2.0-3.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 3.0-4.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 4.0-5.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 5.0-6.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 6.0-7.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 7.0-8.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 8.0-9.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites oleuropein is between about 9.0-10.0 mg/gr, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolites verbascoside is between about 4.1-151.1 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 4.1-10.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 10.0-20.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 20.0-30.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 30.0-40.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 40.0-50.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 50.0-60.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 60.0-70.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 70.0-80.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 80.0-90.0 mg/gr, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 90.0-100.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 100.0-110.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 110.0-120.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 120.0-130.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 130.0-140.0 mg/g, after the olive cell cultures are dried to a powder. According to some embodiments, the amount of the secondary metabolites verbascoside is between about 140.0-151.1 mg/g, after the olive cell cultures are dried to a powder.
- According to some embodiments, the amount of the secondary metabolites hydroxytyrosol, tyrosol, oleuropein and verbascoside in the olive cell cultures, is between about 0.14-15.7, 0.53-21.0, 0.2-10, 4.1-151.1 mg/gr, respectively after the olive cell cultures are dried to a powder.
- According to some embodiments of the invention, the amount of total olive polyphenols including hydroxytyrosol, tyrosol, oleuropein and verbascoside is more than about 1 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 10 mg/gr after the olive cell cultures are dried to a powder According to some embodiments of the invention, the amount is more than about 15 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 25 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 50 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 100 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 150 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 200 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 250 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 300 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 350 mg/gr after the olive cell cultures are dried to a powder. According to some embodiments of the invention, the amount is more than about 400 mg/gr after the olive cell cultures are dried to a powder.
- According to some embodiments, the olive cell cultures prepared according to the large scale method of the invention contain less than about 10% w/v fat. Fat refers to any of a group of natural esters of glycerol and various fatty acids conjugated or free or any combination thereof.
- According to some embodiments, the olive cell cultures contain less than about 5% w/v fat. According to some embodiments, the olive cell cultures contain less than about 3% w/v fat. According to some embodiments, the olive cell cultures contain less than about 2% w/v fat. According to some embodiments, the olive cell cultures contain less than about 1% w/v fat. According to some embodiments, the olive cell cultures contain about 1% w/v fat, As used herein, fat refers to a fat types, e.g., saturated, monounsaturated and polyunsaturated. According to some embodiments, the olive cell cultures are dried, thus concentrating the materials found therein, including the fat. According to some embodiments, the materials are concentrated by a factor of about 5. According to some embodiments, the materials are concentrated by a factor of about 10. According to some embodiments, the materials are concentrated by a factor of about 15. According to some embodiments, the materials are concentrated by a factor of about 20. According to some embodiments, the materials are concentrated by a factor of about 25. According to some embodiments, the materials are concentrated by a factor of about 30.
- In one embodiment of the invention, there is provided a process for the in vitro production of a cell culture of olive fruit/leaf cells grown comprising:
- growing olive cells in a flask;
- inoculating the olive cells from the flask into a first bioreactor; and harvesting the produced olive cells.
- In some embodiments of the invention, there is provided a large scale process for the in vitro production of a cell culture of olive fruit/leaf cells grown comprising:
- growing olive cells in a flask;
- inoculating the olive cells from the flask into a first bioreactor; inoculating the olive cells from the first bioreactor into a second bioreactor, wherein the second bioreactor is a last bioreactor or an intermediate bioreactor, and where there may be provided some more steps with one or more intermediate bioreactors; and
- harvesting the olive cells from the last bioreactor;
- wherein the olive cells harvested from the last bioreactor are dried.
- According to some embodiments, at least one of the bioreactors is a disposable bioreactor.
- By a “disposable bioreactor” it is meant a bioreactor with a disposable bag, which can be for a single use bag instead of a culture vessel. The disposable bag may be prepared from three or more layers of plastic foil. In some embodiments of the invention, one layer is prepared from polyethylene, polyethylene terephthalate or LDPE to provide mechanical stability. A second layer may be prepared using nylon, PVA or PVC that acts as a gas barrier. Finally, a contact layer may be prepared from PVA or PP or another layer of polythyelene, polyethylene terephthalate or LDPE. For medical applications the single-use materials that contact the product must be certified by the European Medicines Agency or similar authorities responsible for other regions.
- According to some embodiments of the invention, the disposable bioreactor is prepared from one or more layers of polyethylene. In some embodiments of the invention, the disposable bioreactor is prepared from an inner and outer layer of polyethylene and a middle nylon layer.
- In general there are two different approaches for constructing single-use bioreactors, differing in the means used to agitate the culture medium.
- Some single-use bioreactors use stirrers, similarly to conventional bioreactors; however, the stirrers may be integrated into the plastic bag. The closed bag and the stirrer are pre-sterilized. In use the bag is mounted in the bioreactor and the stirrer is connected to a driver mechanically or magnetically.
- Other single-use bioreactors are agitated by a rocking motion. Other single-use bioreactors are airlift bioreactor in which the reaction medium is agitated and aerated by introduction of air. This type of bioreactor does not need any mechanical agitators inside the single-use bag.
- According to some embodiments, the large scale process for preparing olive cell cultures comprises a number of subsequent steps. According to some embodiments of the invention, the amount of olive cell cultures prepared in each step is either larger or not than that prepared in the previous step. Further, the olive cell cultures prepared in each step may be inoculated or harvested to be used as a starter for the next step of the large scale process. In the last step of the large scale process, the fruit cells are typically grown until they reach the plateau in their growth profile.
- According to some embodiments, there is provided a composition comprising a complex of pholyphenols including tyrosol, hydroxytyrosol, oleuropein and verbascoside, wherein the amount of verbacoside in respect to the other polyphenols is higher than 1:20. In some embodiments, the ratio is higher than 1:10. In some embodiments, the ratio is higher than 1:5. In some embodiments, the ratio is higher than. In some embodiments, the ratio is higher than 1:3. In some embodiments, the ratio is higher than 1:2.
- According to some embodiments, the composition is derived from a natural source. According to some embodiments, the composition is derived from olive cell cultures grown in large scale disposable bioreactors. According to some embodiments, the composition is derived from olive cell cultures grown in large scale disposable bioreactors, according to the process described herein.
- According to some embodiments, the olive cells are grown in bioreactors. According to some embodiments, the bioreactors are designed so as to allow adequate mixing and mass transfer, while minimizing the intensity of shear stress and hydrodynamic pressure. According to some embodiments of the invention, at least one of the bioreactors is a disposable bioreactor. This can be the first bioreactor or the intermediate bioreactor or the last bioreactor or any combination thereof. According to some embodiments of the invention, the disposable bioreactor is the last bioreactor, such that after growing in the last bioreactor, the cells are harvested therefrom and dried, so as to form a powder.
- According to an exemplary embodiment of the invention, the first step includes the preparation of an olive cell culture in a flask, such as an Erlenmeyer or a bioreactor. According to some embodiments, the first step involves the preparation of up to 1.0 L of an olive cell culture. According to further embodiments, first step involves the preparation of up to 1.5 L of an olive cell culture. According to further embodiments, first step involves the preparation of up to 2.0 L of an olive cell culture.
- According to some embodiments, the first step is conducted using a glass, metal or plastic flask. According to some embodiments, the flask is disposable. According to further embodiments, the flask may be reused any number of times. According to some embodiments, the flask is sterilized by any appropriate means between uses.
- According to some embodiments, the first step includes the use of any appropriate medium for growing the olive cells. According to some embodiments, the medium used for growing the fruit cells includes cell growth medium, salts, vitamins, sugars, hormones or any combination thereof.
- According to further embodiments, the cell growth medium includes O-5, O-4, O-3, M-3medium (as defined in Table 1A) or any combination thereof. According to some embodiments, the cell growth medium is supplemented with sucrose, casein hydrolysate, myoinositol, 1-naphthaleneacetic acid (NAA), kinetin, 2,4,D, written already BA, 2iP, or any combination thereof.
- According to some embodiments, the cell growth medium is supplemented with about 1-6% sucrose, about 0.2-0.3 g/L casein hydrolysate, about 0.05-0.15 g/L myo inositol, about 0.05-0.15 mg/L NAA and/or about 0.1-0.3 mg/L kinetin. According to some embodiments, the pH of the medium is between about 4-6.
- According to some embodiments, the growth medium comprises salts such as magnesium, phosphate, nitrate or any combination thereof. According to some embodiments of the invention, the growth medium includes KNO3, MgSO4, NaH2PO4, or any combination thereof. According to some embodiments, the medium includes vitamins or any combination thereof. According to further embodiments, the medium includes sugars such as sucrose or any combination thereof.
- In an embodiment of the invention, the concentration of the sucrose added to the growth medium is between 1 to 6%. In another embodiment, the concentration of the sucrose added to the growth medium is about 3%.
- According to further embodiments, casein, casein hydrolysate or casein peptone may be included in the cell growth medium. According to further embodiments growth hormones may be included in the cell growth medium. According to further embodiments, the growth medium includes hormones. According to some embodiments the olive cells are grown without the addition of hormones.
- Examples of plant culture media that may be used according to some embodiments in one stage or more of the process, include, but are not limited to: Anderson (Anderson, In Vitro 14:334, 1978; Anderson, Act. Hort., 112:13, 1980), Chee and Pool (Sci. Hort. 32:85, 1987), CLC/Ipomoea (CP) (Chee et al., J. Am. Soc. Hort. Sci. 117:663, 1992), Chu (N.sub.6) (Chu et al., Scientia Sinic. 18:659, 1975; Chu, Proc. Symp. Plant Tiss. Cult., Peking 43, 1978), DCR (Gupta and Durzan, Plant Cell Rep. 4:177, 1985), DKW/Juglans (Driver and Kuniyuki, HortScience 19:507, 1984; McGranahan et al., in: Bonga and Durzan, eds., Cell and Tissue Culture in Forestry, Martinus Nijhoff, Dordrecht, 1987), De Greef and Jacobs (De Greef and Jacobs, Plant Sci. Lett. 17:55, 1979), Eriksson (E R) (Eriksson, Physiol. Plant. 18:976, 1965), Gresshoff and Doy (DBM2) (Gresshoff and Doy, Z Pflanzenphysiol. 73:132, 1974), Heller's (Heller, Ann. Sci. Nat. Bot. Biol. Veg. 11th Ser. 14:1, 1953), Hoagland's (Hoagland and Arnon, Circular 347, Calif. Agr. Exp. Stat., Berkeley, 1950), Kao and Michayluk (Kao and Michayluk, Planta 126:105, 1975), Linsmaier and Skoog (Linsmaier and Skoog, Physiol. Plant. 18:100, 1965), Litvay's (L M) (Litvay et al., Plant Cell Rep. 4:325, 1985), Nitsch and Nitsch (Nitsch and Nitsch, Science 163:85, 1969), Quoirin and Lepoivre (Quoirin et al., C. R. Res. Sta. Cult. Fruit Mar., Gembloux 93, 1977), Schenk and Hildebrandt (Schenk and Hildebrandt, Can. J. Bot. 50:199, 1972), White's (White, The Cultivation of Animal and Plant Cells, Ronald Press, NY, 1963), etc.
- According to some other exemplary embodiments, the olive cells and the medium are continuously mixed during the first step. According to further embodiments, the olive cells and the medium are mixed occasionally during the first step. According to some embodiments, the temperature during the first step is between about 20° C. and 30° C. According to some embodiments, the temperature during the first step is between about 22° C. and 28° C. According to some embodiments, the temperature during the first step is about 25° C. According to some embodiments, the olive cells are grown in the first step for more than 3 days. According to some embodiments, the olive cells are grown in the first step for more than 5 days. According to some embodiments, the olive cells are grown in the first step for more than 3 days and less than 3 weeks.
- According to some exemplary embodiments, the bioreactor used in the process of the invention includes an inlet through which the olive cells from the previous step, the medium and any additional materials are placed into the bioreactor. According to further embodiments, the bioreactor used in the process of the invention includes an outlet for removing any materials desired. According to some embodiments, the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases. According to some embodiments, the gas outlet is operated manually. According to other embodiments, the gas outlet is operated automatically, wherein gases are let out of the flask once the atmosphere in the flask reaches a pre-defined pressure. According to some embodiments, the predefined pressure up to 8 PSI. According to some embodiments, the gas outlet is a separate entity from the outlet for removing liquids/solids.
- Once the first step of the olive cell growth is concluded, according to some exemplary embodiments, the olive cells are inoculated into a small scale bioreactor, which is termed here also the first bioreactor, for the second step of the large scale process. According to some embodiments, the small scale bioreactor is a 4 L reactor. According to further embodiments, the small scale bioreactor is a 3-5 L reactor. According to further embodiments, the small scale bioreactor is a 3-10 L reactor. According to further embodiments, the small scale bioreactor is a 4-8 L reactor.
- The small scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the small scale bioreactor is disposable. If the small scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- As described above, the production of secondary metabolites, including polyphenols, is known to be significantly reduced with increasing bioreactors volumes, in comparison to the amount of the same metabolites in small scale productions, using, e.g., glass flasks, such as Erlenmeyers. However, the large scale process detailed herein provides olive cells in which the amount of the secondary metabolites is not reduced when grown in bioreactors. Further, the production of certain secondary metabolites may even be amplified.
- Thus, according to embodiments of the invention, the relative amounts of the secondary metabolites in olive cells grown in the small scale bioreactor are not significantly reduced in comparison to their relative amounts in the first step of the process. According to some embodiments, the components described above for use in the growth medium in the first step may be used also in the second step of the process. According to some embodiments, the growth medium used in the small scale bioreactor is the same as used in the first step of the large scale process. According to some embodiments, the relative amounts of the different components found in the growth medium in the second step, is the same as in the first step. According to other embodiments, the relative amounts of the different components found in the growth medium in the second step, differ from the relative amounts used in the first step. According to some embodiments, additional materials are added to the growth medium in the second step of the process.
- According to some embodiments, the small scale bioreactor includes an inlet through which the fruit cells from the first step, air, the medium and any additional materials are placed into the bioreactor. According to further embodiments, the small scale bioreactor includes an outlet for removing any materials desired. According to some embodiments, the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases. According to some embodiments, the gas outlet is operated manually. According to other embodiments, the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure. According to some embodiments, the predefined pressure is 8 PSI. According to some embodiments, the gas outlet is a separate entity from the outlet for removing liquids/solids.
- According to some embodiments, the olive cells and the medium are continuously mixed during the second step. According to further embodiments, the olive cells and the medium are mixed occasionally during the second step. According to some embodiments, the temperature during the second step is between about 20 to 30° C. According to some embodiments, the temperature during the second step is between about 22 to 28° C. According to some embodiments, the temperature during the second step is about 25° C. According to some embodiments, the olive cells are grown in the second step for more than a week and less than two weeks. According to some embodiments, the olive cells are grown in the second step for less than a week. In some embodiments of the invention, the olive cells are grown between 4-30 days before being inoculated into the next bioreactor.
- According to some embodiments, for the third step of the large scale process, the harvested olive cells are placed into a medium scale bioreactor. According to some embodiments, the medium scale bioreactor is a 30-50 L reactor. According to further embodiments, the medium scale bioreactor is a 40-60 L reactor. According to further embodiments, the medium scale bioreactor is a 30-70 L reactor. According to further embodiments, the medium scale bioreactor is a 20-100 L reactor.
- The medium scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the medium bioreactor is disposable. If the medium scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- Similarly to the small scale bioreactor, according to embodiments of the invention, the relative amounts of the secondary metabolites in olive cells grown in the medium scale bioreactor are not significantly reduced in comparison to their relative amounts in any of the previous steps of the process. According to some embodiments, the components described above for use in the growth medium in any of the previous steps may be used also in the third step of the process. According to some embodiments, the growth medium used in the medium scale bioreactor is the same as used in any of the previous steps of the medium scale process. According to some embodiments, the relative amounts of the different components found in the growth medium in the third step, is the same as in any of the previous steps of the process. According to other embodiments, the relative amounts of the different components found in the growth medium in the third step, differs from the relative amounts used in any of the previous steps of the process. According to some embodiments, additional materials are added to the growth medium in the third step of the process.
- According to some embodiments, the medium scale bioreactor includes an inlet through which the olive cells from the second step, the medium, air and any additional materials are placed into the bioreactor. According to further embodiments, the medium scale bioreactor includes an outlet for removing any materials desired. According to some embodiments, the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases. According to some embodiments, the gas outlet is operated manually. According to other embodiments, the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure. According to some embodiments, the predefined pressure is up to 8 PSI. according to some embodiments, the gas outlet is a separate entity from the outlet for liquids/solids.
- According to some exemplary embodiments, the olive cells and the medium are continuously mixed during the third step. According to further embodiments, the olive cells and the medium are mixed occasionally during the third step. According to some embodiments, the temperature during the third step is between about 20 and 30° C. According to some embodiments, the temperature during the third step is between about 22 and 28° C. According to some embodiments, the temperature during the third step is about 25° C. According to some embodiments, the olive cells are grown in the third step for about two to three weeks. According to some embodiments, the olive cells are grown in the third step for less than one week. According to some embodiments, the olive cells are grown in the third step for about one to two weeks. According to some embodiments, the olive cells are grown in the third step for about three to five weeks. According to some embodiments, the olive cells are grown in the third step for about 5 to 30 days.
- Once the third step of the olive cell growth is concluded, the olive cells may be inoculated from the medium scale bioreactor typically by any appropriate means. For the fourth exemplary step of the large scale process, the harvested olive cells are placed into a larger scale bioreactor. According to some embodiments, the larger scale bioreactor is a 1000 L reactor. According to further embodiments, the larger scale bioreactor is a 200-500 L reactor. According to further embodiments, the large scale bioreactor is a 500-1000 L reactor. According to further embodiments, the large scale bioreactor is a 1000-1500 L reactor. According to further embodiments, the large scale bioreactor is a 500-1100 L reactor.
- The larger scale bioreactor may be prepared from any appropriate material, such as glass, metal, plastic and/or any type of polymer. According to some embodiments, the larger scale bioreactor is disposable. If the larger scale bioreactor is not disposable, according to some embodiments, it is cleaned and sterilized between uses by any appropriate means.
- Similarly to the small scale bioreactors, according to embodiments of the invention, the relative amounts of the secondary metabolites in olive cells grown in the larger scale bioreactor are not significantly reduced in comparison to their relative amounts in the previous steps of the process. According to some embodiments, the components described above for use in the growth medium in any of the previous steps may be used also in the fourth step of the process. According to some embodiments, the growth medium used in the larger scale bioreactor is the same as used in any of the previous steps. According to some embodiments, the relative amounts of the different components found in the growth medium in the fourth step, is the same as in any of the previous steps. According to other embodiments, the relative amounts of the different components found in the growth medium in the fourth step, differs from the relative amounts used in any of the previous steps. According to some embodiments, additional materials are added to the growth medium in the fourth step of the process.
- According to some embodiments, the larger scale bioreactor includes an inlet through which the olive cells from the third or second step, the medium and any additional materials are placed into the bioreactor. According to further embodiments, the larger scale bioreactor includes an outlet for removing any materials desired. According to some embodiments, the outlet includes a gas outlet, designed to relieve the bioreactor of excess gases. According to some embodiments, the gas outlet is operated manually. According to other embodiments, the gas outlet is operated automatically, wherein gases are let out of the bioreactor once the atmosphere in the bioreactor reaches a pre-defined pressure. According to some embodiments, the predefined pressure is up to 8 PSI. According to some embodiments, the gas outlet is a separate entity from the outlet for liquids/solids.
- According to some embodiments, here and in any other appropriate bioreactor, the bioreactor may include two or more inlets and/or outlets. Each inlet and/or outlet may be designated for the passage of a certain type of material or otherwise, various materials may pass through the same inlet/outlet. The various materials may pass through the inlet/outlet together or separately from one another. Any bioreactor related to herein may further include two or more inlets/outlets designated for the passage of at least one type of material.
- According to some embodiments, the olive cells and the medium are continuously mixed during the fourth step. According to further embodiments, the olive cells and the medium are mixed occasionally during the fourth step. According to some embodiments, the temperature during the fourth step is between about 20 to 30° C. According to some embodiments, the temperature during the fourth step is between about 22 to 28° C. According to some embodiments, the temperature during the fourth step is about 25° C. According to some embodiments, the olive cells are grown in the third or fourth step until they reached a cell biomass of 10% to 70% w/w of the entire mass of the medium.
- According to some embodiments, the large scale process is terminated after the olive cells are grown in the larger scale bioreactor. According to such embodiments, the olive cells are grown in the larger scale bioreactor until they reach a cell biomass of 10% to 70% w/w. Once the cell biomass of 10% to 70% w/w is reached, the olive cells are harvested from the large scale bioreactor by any appropriate means and are further processed. According to some embodiments, the olive cells are further processed by ant appropriate type of drying, lyophilization, Freeze-Drying, fluidized bed air drying and Spray Drying. According to some embodiments, the processing of the olive cells does not include the extraction of active ingredients therefrom.
- According to some embodiments, the large scale process may include one step of inoculating the cells from a flask into a bioreactor, which can be in any size, and harvesting the cells. According to other embodiments, the olive cells may be inoculated in a series of bioreactors wherein each of the bioreactors is typically larger than the previous bioreactor used. Any number of additional steps is performed according to the large scale process. The additional steps include possible intermediate steps in which the cells are harvested or inoculated and placed in a larger bioreactor and grown there until being harvested or inoculated and transferred to a larger bioreactor. According to further embodiments, the process includes additional steps for growing the olive cells harvested from the large scale bioreactor.
- In an embodiment of the invention, there is provided a pharmaceutical or nutraceutical composition or a food additive comprising the olive cells manufactured in the large scale process of the invention. The pharmaceutical or nutraceutical composition or a food additive may be administered to the subject by oral administration.
- As used herein, the phrase “pharmaceutical composition” refers to a preparation of olive cell culture, as further described hereinabove, with or without other chemical components, such as physiologically suitable carriers and excipients.
- In an embodiment of the invention, there is provided a method of treating an inflammatory as well as prevention and/or treatment of risk factors for cardiovascular disease, development of atherosclerotic plaque, protection of LDL particles from oxidative damage, maintenance of normal blood HDL-cholesterol concentrations to decrease blood pressure and to maintain normal haemostatic function. Olive polyphenols were shown to have beneficial effects on learning and memory deficits found in ageing and diseases, such as those related to the overproduction of amyloid-beta peptide. In addition, olive polyphenols were shown to influence gut microbial balance by promoting growth of bacteria influencing lipid metabolism and inhibition of pathogenic bacteria, as well as increase bone density. The method comprises administering to a subject in need a pharmaceutical or nutraceutical composition or a food additive comprising the olive cell culture, wherein the culture is possibly manufactured according to the large scale process detailed herein and is possibly rich in secondary metabolites.
- As used herein the term “treating” refers to the prevention of some or all of the symptoms associated with an inflammatory disease, a condition or disorder. The term “treating” also refers to alleviating the symptoms or underlying cause of an inflammatory disease, prolongation of life expectancy of patients having a disease, as well as complete recovery from a disease.
- Examples of such diseases and conditions that may be treated by the compositions of the invention are detailed herein.
- Metabolic abnormalities are associated with obesity, insulin resistance glucose intolerance, type II diabetes mellitus (DMII), dyslipidemia fatty liver, steatohepatitis, and steatosis. These abnormalities increase the risk of stroke cardio-vascular diseases. The etiology of the metabolic syndrome is considered to be multifactorial involving genetic and environmental effects.
- Metabolic syndrome also known as “the deadly quartet” or “Syndrome X” or the “Insulin Resistance Syndrome” is a cluster of risk factors for various diseases, such as cardio-vascular diseases, stroke and diabetes mellitus type II, i.e. insulin resistance, hyperinsulinemia, abdominal obesity, (caused by an accumulation of intra-abdominal fat), elevated serum lipids, and high blood pressure. 25% of adults living in the United States are diagnosed with metabolic syndrome. It is believed that the pathophysiology of the metabolic syndrome is related to insulin resistance. The risk factors include the following: elevated waist circumference (≥102 cm in man and 88 cm in women); elevated triglycerides (>150 mg/dL); reduced high-density lipoprotein (HDL) cholesterol (<40 mg/dL in men and 50 mg/dL in women); elevated blood pressure (>130/85 mm Hg) and elevated fasting glucose (>100 mg/dL. Other risk factors may contribute to the metabolic syndrome as well. Additionally, the risk factors may vary in different populations.
- Various aspects of the invention are described in greater detail in the following Examples, which represent embodiments of this invention, and are by no means to be interpreted as limiting the scope of this invention.
- Olive cell culture was initiated from olive fruits (Olea europaea L.) of Nabali, Manzanilla, Souri and Barnea cultivars, including all leaves, petioles, fruits and kernels.
- Olive plant parts: young leaves and their petriols, immature fruits (about 6 weeks from flowering) and kernels from immature olives were rinsed under running water and sterilized by agitation in 70% ethanol for three minutes and then 3% Na-hypochlorite solution for 20 minutes, followed by three washes in sterile water. Plant parts were dried under sterile conditions and further dissected into ˜0.5 cm sections.
- Olive plant explants were plated on MS Murashige and Skoog medium basal medium (Table 1B) supplemented with sucrose and various combinations of the
auxines 2,4-dichlorophenoxyacetic acid (2,4-D), 1-naphthaleneacetic acid (NAA) and the cytokinines kinetin, 6-(γ,γ-Dimethylallylamino)purine (2iP) and benzyladenine (BA) at various concentrations. One medium composition (O-2) included active charcoal. The pH of the medium was 5.8. The medium was solidified with agar (Gelrite, Duchefa or Phytagel, Sigma). Plate compositions are specified in Table 1A. Plates were kept at 25° C. in the dark. When formed calli reached a diameter of 1 cm, they were split in a 1:3 ratio onto a similar medium. Calli were transferred to fresh plates every 4 weeks. - Culture growth: Fifty three calli were successfully developed from olive explants (see Table 2). It is noted that the calli development was similar for the Nabali, Manzanilla and Barnea cultivar and lower for the Souri cv.
-
TABLE 2 The efficiency of olive calli production from various olive fruit sections of Nabali, Manzanilla, Barnea and Souri cultivars Total Calli Calli Calli Calli number from from from from Cultivar of calli Leaf petiole fruit kernel Nabali 17 2 3 6 6 Souri 7 1 0 3 3 Manzanilla 15 2 0 11 2 Barnea 14 2 2 7 3 Total 53 7 5 30 14 - The effect of media composition: Calli growth was detected on MS plates including various media components M-3, O-1, O-2, O-3, O-4 and O-5 (see Table 1A). However, as can be seen in Table 3, the most callus development-promoting media compositions were the following: Half-strength MS including 3% sucrose, 2 mg/L NAA and 0.5 mg/L 2iP (O-5, 31 calli) and to a lower extent on full-strength MS including 4.5% sucrose, 0.5 mg/
L L -
TABLE 3 The efficiency of olive calli production (number of well-established calli) on various MS plates Medium composition M-3 0-1 0-2 0-3 0-4 0-5 Nabali 0 0 0 0 7 10 Souri 0 0 0 2 0 5 Manzanilla 0 0 0 3 3 9 Barnea 3 0 0 3 1 7 Total 3 0 0 8 11 31 number of calli - Several different calli were transferred to liquid media for the generation of suspension cultures. Olive suspension culture growth was efficient in liquid, O-5, O-4, O-3 and M-3 medium supplemented with vitamins, minerals, and sugar, as detailed in Table 1A above, apart from the agar, which was not added to the suspension medium; rather, Agar was added only to the medium in which the olive calli were grown. The pH of the suspension medium is between pH of between 4-6 .
- The suspension cultures maintained stable growth in suspension (50 to 1000 ml Erlenmeyer flasks). Cultures were routinely subcultured every 7-20 days to fresh growth media.
- Olive cells were grown in suspension under continuous fluorescent light (1000 1×) at 25+5° C., in 1 liter Erlenmeyer flasks on an orbital shaker.
- The cultured olive cells grown in liquid medium were filtered through filter and dried by lyophilization or spray dryer
- Polyphenols extraction for HPLC analysis: Fresh olive Callus cell cultures were extracted for analytical determination of polyphenol content in the olive culture. About 1 gr of callus was harvested and kept at −20° C. for at least 16 h before analysis. The callus was extracted by 80% methanol/water solution in a ratio of 0.4 ml methanol per 1 gr of cells. The suspension was sonicated for 10 minutes at 30° C. in a sonicator. The solution was centrifuged and the supernatant was re-centrifuged, filtered through a 0.45 μm filter and used for the HPLC analysis.
- Olive tissues (fruits and leaves) were crushed under liquid nitrogen and extracted as described above, the extract was analyzed by HPLC and used as a reference for olive polyphenols content.
- Olive calli extract was analyzed by LC-MS. The method is described in: Food Chemistry 138 (2013) 1381-1391.
- Olive calli samples were extracted in methanol (400 μl/1 gr of calli's fresh weight), as described above. The content of olive polyphenols was determined as follows: hydroxytyrosol, oleuropein and pinoresinol were detected at 280 nm. Tyrosol was detected at 275 nm and verbascoside was detected at 330 nm. Total polyphenols were monitored at 280 nm using commercial Epicatechin (Sigma) as a standard, and expressed as μg epicatechin equivalent.
- Polyphenolic compounds in olive-derived cultures were characterized and quantitated by high performance liquid chromatography (HPLC) analysis. Selected phenolic compounds were identified by their UV absorbance spectra and retention times. Their concentrations were determined by means of a calibration curve using different external standards. Analysis was performed by JASCO PU-2089 HPLC system using the operation software ChromNAV. Total polyphenols were determined by summing AUC of peaks as monitored at 280 nm, and quantified, based on epicatechin as a standard. Total polyphenols is expressed as epicatechin equivalents. Hydroxytyrosol, Oleuropein and pinoresinol were analyzed based on characteristic absorption at 280 nm. Similarly, tyrosol was detected at 275 nm and verbascoside was detected at 330 nm. Compounds were quantified according to standard curves of commercial standards, respectively.
- LC-MS analysis of the sample was performed using an Accela LC system coupled with an LTQ Orbitrap Discovery hybrid FT mass spectrometer (Thermo Fisher Scientific Inc.) equipped with an electrospray ionization source. The mass spectrometer was operated in a negative ionization mode, wherein the ion source parameters were as follows: spray voltage 3.5 kV, capillary temperature 300° C., and ion-transfer optics parameters were optimized using automatic tune option, sheath gas rate (arb) 35, and auxiliary gas rate (arb) 15.
- Mass spectra were acquired in the m/z 150-2000 Da range. The LC-MS analysis was performed in data depending acquisition mode. The LC-MS system was controlled and the data were analyzed using Xcalibur software (Thermo Fisher Scientific Inc). Chromatographic separation was achieved on Kinetex Hexyl-Phenyl column (2.6 μm, 150×2.1 mm, Phenomenex) using an ACN/Water +0.1% AcOH (in both) gradient.
- Expression of various polyphenolic compounds that are produced in olive fruit was also detected in olive calli and in suspension cultures. Amongst these compounds, hydroxytyrosol, tyrosol, oleuropein, verbascoside and pinoresinol were detected, as confirmed by LC-MS. (Table 4).
-
TABLE 4 Expression of olive polyphenols in representative olive calli of four cultivars: Nabali (callus originated from petiole), Souri (callus originated from leaf) Manzanillo (callus originated from leaf) and Barnea (callus originated from pulp) Phenolic compounds in olive calli and cell culture (μg/mg Dry Weight (DW). Nabali Souri Manzanilo Barnea 3,4-DHPEA 1.963 0.785 0.339 0.281 (hydrosytyrosol) p-HPEA (tyrosol) 2.557 4.191 1.075 3.034 Oleuropein 10.0 6 4 2 Verbascoside 37.785 15.925 24.037 8.212 (+)-pinoresinol 0.090 0.000 0.000 0.000 - Hydroxytirosol content in various olive calli cultures ranged from 0.281 to 1.963 μg/mg of dry-weight (DW). Tyrosol content ranged from 1.075 to 4.191 μg/mg of DW. Oleuropein content ranged from 2-10 μg/mg (DW). Verbascoside content ranged from 8.212 to 37.78 μg/mg DW, and pinoresinol was detected only in callus of Nabali cv. Origin, at 0.09 μg/mg DW, considering a drying factor of 20. The content of these compounds in different parts of olive plant as compared to olive calli as well as in cell suspension cultures and bioreactors is summarized in Table 5. The concentrations of active compounds found in olive calli are within the range of these compounds in green olives (Alagna et al., 2012, phenol explorer database). Moreover, the production of high verbascoside concentrations characterizes early maturation stages of olive fruit, and was not shown in calli generated by others, whereas the verbascoside expression in the calli presented here and prepared according to this invention, is stable and is not limited to any development stage.
-
TABLE 5 Polyphenols content in olive plant parts from prior art documents (source: phenol explorer) compared to the olive cells of the invention-fresh weight (FW) and dry weight (DW). Drying factor is 20. A. DATA regarding polyphenols concentration in olives from scientific literature Content in green Content in olives jasmonate (http://phenol- induced Callus explorer.eu/) (Gentile et (mg/g FW) al., 2014) Mean Min. Max. (mg/g DW) Hydrosytyrosol 0.5557 0.043 1.16 1.72 Tyrosol 0.0747 0 0.21 0.34 Verbascoside 0.172 0 0.665 0.56 Oleuropein 0.55 0 3.25 4.66 (+)-pinoresinol ND ND ND ND Luigi Gentile and Nicola A. Uccella, (2014), Selected bioactives from callus cultures of olives (Olea europaea L. Var. Coratina) by LC-MS, Food Research International 55: 128-136. B. Data regarding polyphenols concentration in the invention olive cells grown in vitro Content in the callus culture, cell suspension cultures and bioreactors of the invention mg/g FW mg/g DW Min. Max. Min. Max. Hydrosytyrosol 0.007 0.78 0.14 15.7 Tyrosol 0.027 1.1 0.5375 21.0 Verbascoside 0.21 7.6 4.1 151.1 Oleuropein 0.010 0.5 0.2 10 (+)-pinoresinol 0.000 0.004 0.000 0.090 - Stage 1: cells are prepared and grown as described in example 1.
- Stage 2: Small scale bioreactor
- Small scale bioreactor culturing is performed by inoculating a 7 to 16 old day cell suspensions grown in the Erlenmeyer of Stage 1 into a 4-8 liter disposable bioreactor at 25 +5° C. The cells were grown in the suspension under continuous fluorescent light (1000 1×) in a growing medium containing modified MS supplemented with sucrose 1-6% and the Kinetin, 2,4,D, NAA, BA, 2iP and casein hydrolysate or a combination thereof
- (pH 4.0-6.0)-. The cells were sub-cultured every 5-21 days.
- Stage 3: Large scale bioreactor
- The cell suspensions grown in a small scale biorcactor were inoculated into a 30-50 liter disposable bioreactor. The cells were grown in a suspension under continuous fluorescent light (1000 1×) at 25+5° C. The growing medium containing
-
- Modified MS supplemented with sucrose 1-6% and the Kinetin, 2,4,D, NAA, BA, 2iP and casein hydrolysate or a combination thereof
- (pH 4.0-6.000). The cells were sub-cultured every 5-30 days.
- Stage 4: Larger scale bioreactor
- The cell suspension grown in the small or large scale bioreactor is inoculated into a 300-1000 liter disposable bioreactor. The cells were grown in a suspension under continuous fluorescent light (1000 1×) at 25+5° C.
- The growing medium contained modified MS supplemented with sucrose 1-6% and the Kinetin, 2,4,D, NAA, BA, 2iP and casein hydrolysate or a combination thereof
-
- Stage 5: Harvesting
- The cells were harvested once they reached a cell biomass of 10% to 70% (w\v). The harvested cells were dried (in a spray dryer or lyophilized) to produce a fine green powder, with a typical composition, taste and odor.
- Olive Cells were grown in an Erlenmeyer shake flask in different medium compositions: O4 (modified MS supplemented with sugar hormones), and Gamborg B5. The results are presented in Table 7, demonstrating that olive cells grown in O4 produce approximately 1.9 higher biomass than cells grown in Gamborg B5 medium.
-
TABLE 7 The effect medium composition on growth of Olive cells Fresh weight Medium g/L O4 (modified MS) 134.9 Gamborg B5 72.4 - Olive cells were grown in large bioreactors in different medium compositions: O4 (modified MS) and Gamborg B5. The results, obtained on day 5, are presented in Table 8. The results in Table 8 demonstrate that cells grown in the O4 medium produces three olive polyphenols, i.e., tyrosol, hydroxytyrosol, and oleorupein, which are not detected in the olive cells grown in Gamborg B5.
- Table 8 further shows that olive cells grown in O-4 medium produce approximately 2.65 higher verbascoside levels than olive cells grown in the Gamborg B5 medium.
- Further, as shown in the fresh mass presented in Table 8, olive cells grown in the O-4 medium resulted in a higher biomass in large bioreactor after 5 days in comparison to the biomass obtained for olive cells grown in the Gamborg B5 medium.
-
TABLE 8 The effect of medium composition on growth of Olive cells in large bioreactor and their polyphenols levels as measured by HPLC at 280 nm Fresh *weight Tyrosol Hydroxytyrosol Oleuropein Verbascoside Medium g/L mg/L mg/L mg/L mg/L O4 (modified 76 12.54 4.71 2.36 949.24 MS) Gamborg B5 48 N.D N.D N.D 358.56 *MS-Murashige and Skoog medium (Toshio Murashige and Folke K. Skoog in 1968) - The effect of growing in vitro the olive cells in dark conditions was tested. Cell growth was assessed by the measurement the fresh weight of the cells grown in vitro, demonstrating that olive cells are growing in both conditions with slightly favorite to dark condition (Table 9).
-
TABLE 9 The effect of growing conditions light and Dark conditions on growth of olive cells in large bioreactors Growing Fresh weight Conditions g/L O4 (modified MS) light 63 O4 (modified MS) dark 103 - Olive Cells were grown in O-4 medium, namely modified MS medium with additional agents defined as O-4, in disposable large bioreactors. The results reveal that cells undergo exponential growth yielding a 200 gr/; fresh biomass at day 10 (
FIG. 2 ). It is noted that these cells continue to grow, and can reach higher biomasses than presented. - This is the first time that the successful growth of olive cells in a large scale disposable bioreactor, having a high level of polyphenols production such as, Tyrosol, Hydrixityrosol, oleoropein and verbascoside, has been demonstrated.
- As described above, the production of secondary metabolites, including polyphenols, such as tyrosol and verbascoside, is expected to be significantly reduced when larger quantities of olive cells are grown in bioreactors, in comparison to the amount of the same metabolites in small scale productions, using, e.g., glass flasks, such as Erlenmeyers. However, the large scale process detailed herein provides olive cells in which the amount of the secondary metabolites is not reduced when grown in bioreactors. Further, the production of certain secondary metabolites may even be amplified.
- While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
Claims (17)
1. A large scale process for the in vitro production of an olive cell culture of olive leaf, seed or olive fruit cells grown in vitro, wherein the olive fruit/seed/leaf cells grown in vitro comprises verbascoside in the amount of at least 4.1 mg/gr dry weight comprising:
growing olive cells in a flask;
inoculating the olive cells from the flask into a first bioreactor;
inoculating the olive cells from the first bioreactor into a second bioreactor;
optionally inoculating the olive cells from the second bioreactor into a last bioreactor; and
harvesting the olive cells from the last bioreactor;
wherein the second bioreactor is a last bioreactor or an intermediate bioreactor and wherein the olive cells harvested from the last bioreactor are dried and wherein the olive cells are grown in a modified MS growth medium enriched with sucrose, casein hydrolysate, myo inositol, 1-naphthaleneacetic acid (NAA), kinetin, 2,4,D, NAA, BA, 2iP, or any combination thereof.
2. The large scale process of claim 1 , wherein the size of each bioreactor used in the process is larger than the one in which the olive cells were previously grown.
3. The large scale process of claim 1 , wherein if the second bioreactor is an intermediate bioreactor, an additional step of inoculating the olive cells to another intermediate bioreactor or to the last bioreactor is performed.
4. The large scale process according to claim 1 , further including additional steps of inoculating the olive cells from the second bioreactor into any number of sequential intermediate bioreactors.
5. The large scale process of claim 1 , wherein any one of the bioreactors is a 4-10 liter bioreactor.
6. The large scale process of claim 1 , wherein any one of the bioreactors is a 10-50 liter bioreactor.
7. The large scale process of claim 1 , wherein any one of the bioreactors is a 50-200 liter bioreactor.
8. The large scale process of claim 1 , wherein any one of the bioreactors is a 200-500 liter bioreactor.
9. The large scale process of claim 1 , any one of the bioreactors is a 200-1000 liter bioreactor.
10. The large scale process of claim 1 , wherein at least one bioreactor is a disposable bioreactor.
11. The large scale process of claim 10 , wherein the disposable bioreactor is made from one or more layers of polyethylene.
12. The large scale process of claim 11 , wherein the disposable bioreactor includes an inner and an outer layer prepared from polyethylene and a middle layer prepared from nylon.
13. The large scale process of claim 11 , wherein the growth medium does not include plant hormones.
14. The large scale process of claim 11 , wherein the growth medium includes plant hormones.
15. The large scale process of claim 1 , wherein the growth medium is enriched with 1-6% sucrose.
16. The large scale process of claim 1 , wherein the modified MS growth medium for growing olive calli comprises:
a) 1.1-8.8 gr/L MS medium, 0.5 mg/L kinetin, 0.5 mg/L 2,4,D, 40 gr/L sucrose and 6 gr/L agar;
b) 1.1-8.8 gr/L MS medium, 1.3 mg/L 2,4,D, 0.06 mg/L BA, 30 gr/L sucrose and 6 gr/L agar;
c) 1.1-8.8 gr/L MS medium, 2.6 mg/L 2,4,D, 0.12 mg/L BA, 30 gr/L sucrose, 0.25 gr/L charcoal, and 6 gr/L agar;
d) 1.1-8.8 gr/L MS medium, 0.1 mg/L 2,4,D, 20 gr/L sucrose, and 6 gr/L agar;
e) 1.1-8.8gr/L MS medium, 0.5 mg/L 2,4,D, 0.1 mg/L 2iP, 45 gr/L sucrose, and 6 gr/L agar; or
f) 1.1-8.8 gr/L MS medium, 2.0 mg/L NAA, 0.5 mg/L 2iP, 30 gr/L sucrose, and 6 gr/L agar.
17. The large scale process of claim 1 , wherein the modified MS growth medium for growing olive cells in vitro in bioreactor comprises:
1.1-8.8 gr/L MS medium, 0.5 mg/L kinetin, 0.5 mg/L 2,4,D, and 40 gr/L sucrose;
1.1-8.8 gr/L MS medium, 1.3 mg/L 2,4,D, 0.06 mg/L BA, 30 gr/L and sucrose;
1.1-8.8 gr/L MS medium, 2.6 mg/L 2,4,D, 0.12 mg/L BA and 30 gr/L sucrose;
1.1-8.8 gr/L MS medium, 0.1 mg/L 2,4,D and 20 gr/L sucrose;
1.1-8.8 gr/L MS medium, 0.5 mg/L 2,4,D, 0.1 mg/L 2iP and 45 gr/L sucrose; or
1.1-8.8 gr/L MS medium, 2.0 mg/L NAA, 0.5 mg/L 2iP and 30 gr/L sucrose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/155,059 US20210138015A1 (en) | 2016-01-27 | 2021-01-21 | Olive derived cell culture and methods for preparing and using the same |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662287453P | 2016-01-27 | 2016-01-27 | |
PCT/IL2017/050098 WO2017130199A1 (en) | 2016-01-27 | 2017-01-26 | Olive derived cell culture and methods for preparing and using the same |
US201816072886A | 2018-07-26 | 2018-07-26 | |
US17/155,059 US20210138015A1 (en) | 2016-01-27 | 2021-01-21 | Olive derived cell culture and methods for preparing and using the same |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/072,886 Continuation US20190231837A1 (en) | 2016-01-27 | 2017-01-26 | Olive derived cell culture and methods for preparing and using the same |
PCT/IL2017/050098 Continuation WO2017130199A1 (en) | 2016-01-27 | 2017-01-26 | Olive derived cell culture and methods for preparing and using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210138015A1 true US20210138015A1 (en) | 2021-05-13 |
Family
ID=59397547
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/072,886 Abandoned US20190231837A1 (en) | 2016-01-27 | 2017-01-26 | Olive derived cell culture and methods for preparing and using the same |
US17/155,059 Pending US20210138015A1 (en) | 2016-01-27 | 2021-01-21 | Olive derived cell culture and methods for preparing and using the same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/072,886 Abandoned US20190231837A1 (en) | 2016-01-27 | 2017-01-26 | Olive derived cell culture and methods for preparing and using the same |
Country Status (2)
Country | Link |
---|---|
US (2) | US20190231837A1 (en) |
WO (1) | WO2017130199A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109439548A (en) * | 2018-11-15 | 2019-03-08 | 中国科学院成都生物研究所 | A kind of strengthening porcelain and Preparation method and use that can generate tyrosol and hydroxytyrosol |
CN113854283A (en) * | 2021-09-06 | 2021-12-31 | 中国林业科学研究院亚热带林业研究所 | Ultralow-temperature cryopreservation method for olive embryogenic callus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7390641B2 (en) * | 2004-05-25 | 2008-06-24 | Council Of Scientific And Industrial Research | Production of peroxidase from plant cell and callus cultures |
US20090305338A1 (en) * | 2006-09-29 | 2009-12-10 | Anneli Ritala-Nurmi | Plant cell lines established from the medicinal plant veratrum californicum |
DK2338550T3 (en) * | 2009-11-18 | 2012-05-21 | Hoffmann La Roche | Cartridge detection |
US20140087026A1 (en) * | 2012-09-26 | 2014-03-27 | Dianaplantsciences, S.A.S. | Novel food composition of whole plant cells |
US10538737B2 (en) * | 2014-01-05 | 2020-01-21 | Bio Harvest Ltd. | Pomegranate derived cell culture and methods for preparing and using the same |
-
2017
- 2017-01-26 WO PCT/IL2017/050098 patent/WO2017130199A1/en active Application Filing
- 2017-01-26 US US16/072,886 patent/US20190231837A1/en not_active Abandoned
-
2021
- 2021-01-21 US US17/155,059 patent/US20210138015A1/en active Pending
Non-Patent Citations (4)
Title |
---|
Alagna et al. Olive phenolic compounds: metabolic and transcriptional profiling during fruit development. BMC Plant Biology (2012), 12:162. (Year: 2012) * |
Murashige and Skoog. A Revised Medium for Rapid Growth and Bio Assays with Tohaoco Tissue Cultures. Physiologia Plantarum (1962), 15, 473-497; (Year: 1962) * |
Ramezani et al. Callus Induction from Anther Explant of Olive (Olea Europaea L.) Influenced by Plant Growth Regulators. Advances in Environmental Biology (2009), 3(1), 21-24. (Year: 2009) * |
Rufoni et al. Plant Cell Cultures: Bioreactors for Industrial Production. Ch. 15 in Advances in Experimental Medicines and Biology (2010), v698, 203-221. (Year: 2010) * |
Also Published As
Publication number | Publication date |
---|---|
WO2017130199A1 (en) | 2017-08-03 |
US20190231837A1 (en) | 2019-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210138015A1 (en) | Olive derived cell culture and methods for preparing and using the same | |
Khalafalla et al. | Antileukemia activity from root cultures of Vernonia amygdalina | |
Shohael et al. | Application of bioreactor system for large-scale production of Eleutherococcus sessiliflorus somatic embryos in an air-lift bioreactor and production of eleutherosides | |
US20120039918A1 (en) | Composition for Enhancing Immunity Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as an Active Ingredient | |
Jang et al. | Production of biomass and bioactive compounds from shoot cultures of Rosa rugosa using a bioreactor culture system | |
Kavianifar et al. | Effects of nano elicitors on callus induction and mucilage production in tissue culture of Linum usitatissimum L. | |
US10538737B2 (en) | Pomegranate derived cell culture and methods for preparing and using the same | |
Sagharyan et al. | Optimization of callus induction with enhancing production of phenolic compounds production and antioxidants activity in callus cultures of Nepeta binaloudensis Jamzad (Lamiaceae) | |
Tošić et al. | Phytochemical composition and biological activities of native and in vitro-propagated Micromeria croatica (Pers.) Schott (Lamiaceae) | |
US20150275169A1 (en) | Process for the large scale production of fruit cells | |
Guha et al. | Antifungal activity of the crude extracts and extracted phenols from gametophytes and sporophytes of two species of Adiantum | |
Françoise et al. | Growth optimization of Zataria multiflora Boiss. tissue cultures and rosmarinic acid production improvement | |
TW200526241A (en) | Processes for producing an antrodia camphorata culture having pharmacological activity, processes for obtaining A pharmacologically active composition from a culture of A. camphorata, products produced thereby and pharmaceutical compositions for ... | |
Baskaran et al. | Acetylcholinesterase-inhibition and antibacterial activity of Mondia whitei adventitious roots and ex vitro-grown somatic embryogenic-biomass | |
Ernst | Pimpinella anisum L.(Anise): Cell culture, somatic embryogenesis, and the production of anise oil | |
US20100285054A1 (en) | Antimicrobial Composition Comprising Fungal Extract, Process for Producing Fungal Extract and Method for Protecting Organisms | |
CN110938582A (en) | Culture medium capable of improving cell proliferation activity and preparation method thereof | |
Tram et al. | Effects of plant growth regulators and sugars on Ehretia asperula Zoll. et Mor. cell cultures | |
KR101188165B1 (en) | Method for increasing productivity of secondary metabolites in Angelica gigas Nakia cell culture by two-stage bioreactor process and elicitation | |
JP2937435B2 (en) | Tissue culture method of woody plant | |
Vani et al. | Photochemical analysis and antibacterial activity Tylophora indica (Burm. F.) Merill | |
Arekemase et al. | The efficacy of extracts of the leaf and bark of cashew plant (Anacardium occidentale) on bacterial isolates isolated from banana (Musa paradisica) | |
MOUBARAK et al. | Potential of hormones combination on callugensis of anise seeds and its antioxidant activity | |
Maliga et al. | The Enhancement of kaempferol by yeast elicitor in callus cultures of Oxystelma esculentum (LF) | |
Elyamany | Treatments of Coleus forskholii that increase rooting to get larger crude forskolin extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIO HARVEST LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAGAY, YOHEVED;AZACHI, MALKIT;REEL/FRAME:054991/0484 Effective date: 20180730 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |